# Pembrolizumab in patients with advanced hepatocellul with sorafenib (KEYNOTE-224): a non-randomised, oper

Lancet Oncology, The

19, 940-952

DOI: 10.1016/s1470-2045(18)30351-6

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 2 | Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89. | 3.0 | 30 |
| 3 | Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 107-107. | 3.0 | 1 |
| 4 | Systemic Therapy for Hepatocellular Carcinoma: Recent Advances. Acta Hepatologica Japonica, 2018, 59, 587-603. | 0.1 | 3 |
| 5 | Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1â€6 hepatocellular carcinoma model. Cancer Science, 2018, 109, 3993-4002. | 3.9 | 215 |
| 6 | Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. Journal of Hepatocellular Carcinoma, 2018, Volume 5, 91-98. | 3.7 | 10 |
| 7 | Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of HepatocellularÂCarcinoma. Gastroenterology, 2018, 155, 1936-1950.e17. | 1.3 | 211 |
| 8 | Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO Open, 2018, 3, e000455. | 4.5 | 76 |
| 9 | Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics, 2018, 8, 5690-5702. | 10.0 | 45 |
| 10 | Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma. Current Hepatology Reports, 2018, 17, 392-398. | 0.9 | 1 |
| 11 | Systemic treatment for hepatocellular carcinoma. Chronic Diseases and Translational Medicine, 2018, 4, 148-155. | 1.2 | 8 |
| 12 | Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers, 2018, 10, 367. | 3.7 | 24 |
| 13 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv238-iv255. | 1.2 | 663 |
| 14 | Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Seminars in Liver Disease, 2018, 38, 379-388. | 3.6 | 62 |
| 15 | Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics, 2018, 73, e510s. | 1.5 | 0 |
| 16 | Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880808. | 3.2 | 10 |
| 17 | Current State of Immunotherapy for HCCâ€"Supporting Data and Toxicity Management. Current Hepatology Reports, 2018, 17, 434-443. | 0.9 | 2 |
| 18 | Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers, 2018, 10, 412. | 3.7 | 138 |
| 19 | Nivolumab for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 1169-1175. | 2.4 | 99 |

| # | Article | IF | Citations |
|---|---|---|---|
| 20 | Molecular heterogeneity in hepatocellular carcinoma. Hepatic Oncology, 2018, 5, HEP10. | 4.2 | 18 |
| 21 | Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-10. | 2.2 | 34 |
| 22 | Shaping the landscape of immune oncology in hepatocellular carcinoma. Lancet Oncology, The, 2018, 19, 855-856. | 10.7 | 2 |
| 24 | Liquid biopsies for hepatocellular carcinoma. Translational Research, 2018, 201, 84-97. | 5.0 | 29 |
| 25 | Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2018, 18, 905-910. | 3.1 | 89 |
| 26 | Emerging therapies in advanced hepatocellular carcinoma. Experimental Hematology and Oncology, 2018, 7, 17. | 5.0 | 85 |
| 28 | Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Alimentary Pharmacology and Therapeutics, 2019, 50, 872-884. | 3.7 | 31 |
| 29 | Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncology, 2019, 15, 2449-2462. | 2.4 | 11 |
| 30 | Immunotherapy for hepatocellular carcinoma: Current and future. World Journal of Gastroenterology, 2019, 25, 2977-2989. | 3.3 | 148 |
| 31 | Prevention Strategies for Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 255-289. | 0.4 | 2 |
| 32 | Early alphaâ€foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189. | 3.9 | 55 |
| 33 | Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 2416-2429. | 3.3 | 66 |
| 34 | Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. Digestive and Liver Disease, 2019, 51, 1488-1490. | 0.9 | 9 |
| 35 | Experimental Models for Preclinical Research in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 333-358. | 0.4 | 7 |
| 36 | Letter: programmed cell death proteinâ€1â€targeted immunotherapy for advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2019, 50, 340-341. | 3.7 | 1 |
| 37 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490. | 7.7 | 57 |
| 38 | The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver International, 2019, 39, 2008-2023. | 3.9 | 56 |
| 39 | Biology and significance of alphaâ€fetoprotein in hepatocellular carcinoma. Liver International, 2019, 39, 2214-2229. | 3.9 | 327 |

| # | Article | IF | Citations |
|---|---|---|---|
| 40 | A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 589-604. | 17.8 | 2,482 |
| 41 | Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 2019, 8, 221-238. | 7.7 | 51 |
| 42 | Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. Cancers, 2019, 11, 1078. | 3.7 | 36 |
| 43 | Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics, 2019, 9, 4678-4687. | 10.0 | 61 |
| 44 | Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers, 2019, 11, 1085. | 3.7 | 60 |
| 45 | Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opinion on Biological Therapy, 2019, 19, 1165-1172. | 3.1 | 40 |
| 46 | Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Seminars in Diagnostic Pathology, 2019, 36, 434-440. | 1.5 | 58 |
| 48 | The alpha and ÃŸeta in phase II trials hepatocellular carcinoma â€•A tale of more than radiological response?. Liver International, 2019, 39, 1391-1393. | 3.9 | 0 |
| 49 | Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World Journal of Gastroenterology, 2019, 25, 3151-3167. | 3.3 | 80 |
| 50 | Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology and Hepatology, 2019, 4, 721-730. | 8.1 | 105 |
| 51 | Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. Journal of Clinical and Experimental Hepatology, 2019, 9, 588-596. | 0.9 | 43 |
| 53 | Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International, 2019, 39, 1608-1621. | 3.9 | 67 |
| 54 | Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease, 2019, 51, 1713-1719. | 0.9 | 18 |
| 55 | Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology, 2019, 31, 560-569. | 1.4 | 6 |
| 56 | Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research, 2019, 7, 1390-1395. | 3.4 | 54 |
| 57 | Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025. | 1.8 | 118 |
| 58 | Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125, 3312-3319. | 4.1 | 90 |
| 59 | Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. , 2019, 7, 193. | | 304 |

| # | Article | IF | Citations |
|---|---|---|---|
| 60 | Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986269. | 3.2 | 75 |
| 61 | Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma. BioScience Trends, 2019, 13, 282-283. | 3.4 | 5 |
| 62 | Immunomodulatory TGF-Î² Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 2019, 25, 1010-1023. | 6.7 | 157 |
| 63 | <p>Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 119-129. | 3.7 | 15 |
| 64 | Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. Nano Letters, 2019, 19, 5266-5276. | 9.1 | 40 |
| 65 | Treatment Lines in Hepatocellular Carcinoma. Visceral Medicine, 2019, 35, 266-272. | 1.3 | 31 |
| 66 | Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers, 2019, 11, 861. | 3.7 | 25 |
| 67 | Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers, 2019, 11, 873. | 3.7 | 19 |
| 68 | Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019, 125, 3603-3614. | 4.1 | 121 |
| 69 | Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cellular Oncology (Dordrecht), 2019, 42, 705-715. | 4.4 | 18 |
| 70 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology, 2019, 8, 1615817. | 4.6 | 85 |
| 71 | Comparison of the current international guidelines on the management of HCC. JHEP Reports, 2019, 1, 114-119. | 4.9 | 30 |
| 72 | Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267. | | 156 |
| 73 | Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina (Lithuania), 2019, 55, 698. | 2.0 | 54 |
| 74 | Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. American Journal of Health-System Pharmacy, 2019, 76, 1749-1752. | 1.0 | 22 |
| 75 | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554. | 3.7 | 73 |
| 76 | Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2019, 28, 941-949. | 4.1 | 25 |
| 77 | Cabozantinib for the treatment of hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 847-855. | 2.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 78 | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinomaâ€"Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers, 2019, 11, 1517. | 3.7 | 30 |
| 79 | <p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166. | 3.7 | 25 |
| 80 | Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689. | 3.7 | 44 |
| 81 | Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 447. | 8.6 | 149 |
| 82 | Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. International Journal of Biological Sciences, 2019, 15, 1905-1920. | 6.4 | 53 |
| 83 | Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers, 2019, 11, 1721. | 3.7 | 8 |
| 84 | Immune checkpoint inhibitorâ€associated pituitaryâ€adrenal dysfunction: A systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 7503-7515. | 2.8 | 35 |
| 85 | Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?. Hepatobiliary Surgery and Nutrition, 2019, 8, 546-548. | 1.5 | 1 |
| 86 | Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer, 2019, 19, 1062. | 2.6 | 19 |
| 87 | Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Current Oncology, 2019, 26, 665-681. | 2.2 | 2 |
| 88 | Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51. | 2.5 | 32 |
| 89 | The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 51-55. | 2.1 | 4 |
| 90 | Emerging agents and regimens for hepatocellular carcinoma. Journal of Hematology and Oncology, 2019, 12, 110. | 17.0 | 71 |
| 91 | Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Frontiers in Oncology, 2019, 9, 1157. | 2.8 | 75 |
| 92 | Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6986-6994. | 2.8 | 37 |
| 93 | Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 423. | 8.6 | 47 |
| 94 | Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Lithuania), 2019, 55, 526. | 2.0 | 147 |
| 95 | Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology, 2019, 71, 1175-1183. | 3.7 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 98 | Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 4307. | 4.1 | 30 |
| 99 | PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2019, 4, 51-51. | 3.0 | 16 |
| 100 | From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 396. | 8.6 | 265 |
| 101 | The potential combinational immunotherapiesfor treatment of hepatocellular carcinoma. Journal of Interventional Medicine, 2019, 2, 47-51. | 0.5 | 3 |
| 102 | The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986976. | 3.2 | 31 |
| 103 | New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma. Clinical Liver Disease, 2019, 14, 56-61. | 2.1 | 23 |
| 104 | Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers, 2019, 11, 1433. | 3.7 | 13 |
| 105 | PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 505-510. | 1.3 | 30 |
| 106 | Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia, 2019, 36, 1002-1010. | 2.5 | 9 |
| 107 | Adoptive cell transfer therapy for hepatocellular carcinoma. Frontiers of Medicine, 2019, 13, 3-11. | 3.4 | 45 |
| 108 | The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608. | 4.2 | 97 |
| 109 | Genomic profiling of combined hepatocellularâ€cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. Journal of Pathology, 2019, 248, 164-178. | 4.5 | 82 |
| 110 | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. Journal of Clinical and Experimental Hepatology, 2019, 9, 221-232. | 0.9 | 167 |
| 111 | An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. Hepatology, 2019, 69, 2518-2532. | 7.3 | 47 |
| 112 | Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 1-11. | 7.7 | 48 |
| 113 | Success of immune checkpoint blockade therapies â€“ mechanisms and implications for hepatology. Zeitschrift Fur Gastroenterologie, 2019, 57, 74-86. | 0.5 | 2 |
| 114 | <p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. Cancer Management and Research, 2019, Volume 11, 4297-4312. | 1.9 | 47 |
| 115 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621. | 3.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 116 | Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 427-446. | 7.7 | 89 |
| 117 | Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 2019, 9, 1050-1060. | 12.0 | 23 |
| 118 | Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepatic Oncology, 2019, 6, HEP11. | 4.2 | 24 |
| 119 | Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells, 2019, 8, 604. | 4.1 | 12 |
| 120 | Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut, 2019, 68, 2019-2031. | 12.1 | 230 |
| 121 | Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459. | 1.2 | 146 |
| 122 | Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers, 2019, 11, 841. | 3.7 | 68 |
| 123 | A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Modern Pathology, 2019, 32, 1646-1656. | 5.5 | 16 |
| 124 | Genomic landscape of lymphoepitheliomaâ€like hepatocellular carcinoma. Journal of Pathology, 2019, 249, 166-172. | 4.5 | 26 |
| 125 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552. | 3.7 | 180 |
| 126 | Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630. | 3.7 | 308 |
| 127 | Nivolumab in patients with advanced hepatocellular carcinoma and Childâ€Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer, 2019, 125, 3234-3241. | 4.1 | 73 |
| 128 | Î²-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€“PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141. | 9.4 | 498 |
| 129 | Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 341-358. | 7.7 | 82 |
| 130 | Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984346. | 3.2 | 19 |
| 131 | <p>Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 71-84. | 3.7 | 54 |
| 132 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 248-260. | 3.8 | 8 |
| 133 | Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 143-154. | 7.7 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 134 | Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. CardioVascular and Interventional Radiology, 2019, 42, 1262-1270. | 2.0 | 2 |
| 135 | Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164. | 3.8 | 459 |
| 136 | Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report. Tohoku Journal of Experimental Medicine, 2019, 247, 247-250. | 1.2 | 4 |
| 137 | Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297. | 1.5 | 66 |
| 138 | Proteomics promises a new era of precision cancer medicine. Signal Transduction and Targeted Therapy, 2019, 4, 13. | 17.1 | 4 |
| 139 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008. | 7.1 | 526 |
| 140 | Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus â€“ case series and literature review. Zeitschrift Fur Gastroenterologie, 2019, 57, 501-507. | 0.5 | 6 |
| 141 | Clinical characteristics and outcomes of candidates for secondâ€line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatology Research, 2019, 49, 1054-1065. | 3.4 | 40 |
| 142 | Implications of Immunotherapy in Hepatobiliary Tumors. Visceral Medicine, 2019, 35, 18-26. | 1.3 | 6 |
| 143 | New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatology International, 2019, 13, 391-394. | 4.2 | 0 |
| 144 | Role of immune checkpoint inhibitors in gastrointestinal cancer treatment. Memo - Magazine of European Medical Oncology, 2019, 12, 71-76. | 0.5 | 2 |
| 145 | From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144. | 5.0 | 52 |
| 146 | Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut, 2019, 68, 1653-1666. | 12.1 | 246 |
| 147 | Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470. | 3.1 | 28 |
| 148 | <scp>MYC</scp> in Germinal Centerâ€derived lymphomas: Mechanisms and therapeutic opportunities. Immunological Reviews, 2019, 288, 178-197. | 6.0 | 42 |
| 149 | Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. Digestive Diseases and Sciences, 2019, 64, 918-927. | 2.3 | 26 |
| 150 | Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research, 2019, 42, 567-581. | 6.3 | 17 |
| 151 | Progression after Immunotherapy for Fibrolamellar Carcinoma. Visceral Medicine, 2019, 35, 39-42. | 1.3 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 152 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist, 2019, 24, S3-S10. | 3.7 | 108 |
| 153 | Immunotherapy: Current Status and Future Perspectives. Digestive Diseases and Sciences, 2019, 64, 1030-1040. | 2.3 | 24 |
| 154 | How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896. | 1.2 | 78 |
| 155 | Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World Journal of Gastroenterology, 2019, 25, 789-807. | 3.3 | 135 |
| 156 | Role of CXCR6 in Antitumor Immune Surveillance. Gastroenterology, 2019, 156, 1565-1568. | 1.3 | 1 |
| 157 | RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncology, 2019, 15, 1811-1822. | 2.4 | 99 |
| 158 | Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29. | 4.9 | 45 |
| 159 | Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462. | 27.0 | 2,966 |
| 160 | Programmed cell death proteinâ€1 (<scp>PD</scp>â€1)â€targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333. | 3.7 | 106 |
| 161 | Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology, 2019, 70, 1437-1442. | 7.3 | 104 |
| 162 | Has PD-1 MET Its Match in Hepatocellular Carcinoma?. Gastroenterology, 2019, 156, 1563-1565. | 1.3 | 1 |
| 163 | Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277. | 3.7 | 150 |
| 164 | A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1984-1991. | 2.8 | 7 |
| 165 | Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. Expert Review of Anticancer Therapy, 2019, 19, 343-353. | 2.4 | 16 |
| 166 | The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Targeted Oncology, 2019, 14, 115-123. | 3.6 | 19 |
| 167 | <p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 31-39. | 3.7 | 55 |
| 168 | Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 19. | 2.8 | 34 |
| 169 | Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surgical Oncology, 2019, 28, 228-235. | 1.6 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 170 | Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. Seminars in Nuclear Medicine, 2019, 49, 170-181. | 4.6 | 8 |
| 171 | Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46. | 1.3 | 6 |
| 172 | Emerging Role of the Pathologist in Precision Medicine for HCC. Digestive Diseases and Sciences, 2019, 64, 928-933. | 2.3 | 5 |
| 173 | Supplementary Sorafenib Therapies for Hepatocellular Carcinomaâ€"A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology, 2019, 53, 486-494. | 2.2 | 6 |
| 175 | Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas. Precision Cancer Medicine, 2019, 2, 36-36. | 1.8 | 1 |
| 176 | Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2055-2066. | 4.2 | 94 |
| 177 | Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2019, 28, 717-729. | 1.5 | 9 |
| 178 | Systemic Therapy for Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 695-715. | 1.5 | 9 |
| 179 | Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306. | 3.1 | 62 |
| 180 | Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353. | | 91 |
| 181 | Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333. | | 129 |
| 182 | The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2019, 18, 371-382. | 0.9 | 0 |
| 183 | Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. , 2019, 7, 322. | | 122 |
| 184 | First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707. | 9.4 | 157 |
| 185 | Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426. | 7.7 | 40 |
| 186 | A Phase 2 Study of Galunisertib (TGF-Î²1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2019, 10, e00056. | 2.5 | 151 |
| 187 | Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926. | 3.7 | 27 |
| 188 | The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. Journal of Oncology, 2019, 2019, 1-22. | 1.3 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 189 | Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date . OncoTargets and Therapy, 2019, Volume 12, 10335-10342. | 2.0 | 19 |
| 190 | Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology, 2019, 10, e00058. | 2.5 | 38 |
| 191 | Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060. | 7.3 | 77 |
| 192 | Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 510-524. | 1.3 | 179 |
| 193 | Sorafenib: key lessons from over 10 years of experience. Expert Review of Anticancer Therapy, 2019, 19, 177-189. | 2.4 | 72 |
| 194 | Evaluation of objective response, disease controlÂand progression-free survival as surrogate end-points for overall survival in antiâ€“programmed death-1 and antiâ€“programmed death ligand 1 trials. European Journal of Cancer, 2019, 106, 1-11. | 2.8 | 37 |
| 195 | Liver damage related to immune checkpoint inhibitors. Hepatology International, 2019, 13, 248-252. | 4.2 | 36 |
| 196 | Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. Future Oncology, 2019, 15, 563-565. | 2.4 | 2 |
| 197 | Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Current Treatment Options in Oncology, 2019, 20, 3. | 3.0 | 26 |
| 198 | Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research, 2019, 25, 515-523. | 7.0 | 354 |
| 199 | Medical oncologists must get more involved in systemic treatment. Annals of Oncology, 2019, 30, 6-8. | 1.2 | 2 |
| 200 | Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clinical and Translational Oncology, 2019, 21, 702-712. | 2.4 | 38 |
| 201 | New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transplantation, 2019, 25, 311-322. | 2.4 | 21 |
| 202 | Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investigational New Drugs, 2019, 37, 567-572. | 2.6 | 44 |
| 203 | Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut, 2020, 69, 365-379. | 12.1 | 117 |
| 204 | Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2020, 31, 25-34. | 0.5 | 72 |
| 205 | 2019 Update of Indian National Association for Study of the LiverÂConsensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. Journal of Clinical and Experimental Hepatology, 2020, 10, 43-80. | 0.9 | 47 |
| 206 | Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics, 2020, 38, 5-24. | 3.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 208 | The Major Histocompatibility Complex Class IIâ€“CD4 Immunologic Synapse in Alcoholic Hepatitis and Autoimmune Liver Pathology. American Journal of Pathology, 2020, 190, 25-32. | 3.8 | 9 |
| 209 | Dual Programmed Death Receptorâ€1 and Vascular Endothelial Growth Factor Receptorâ€2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology, 2020, 71, 1247-1261. | 7.3 | 247 |
| 210 | 4â€1BB Delineates Distinct Activation Status of Exhausted Tumorâ€Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 2020, 71, 955-971. | 7.3 | 70 |
| 211 | The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. Journal of Hepatology, 2020, 72, 167-182. | 3.7 | 116 |
| 212 | Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. Journal of Gastroenterology, 2020, 55, 15-26. | 5.1 | 115 |
| 213 | REFLECTâ€”a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. Journal of Gastroenterology, 2020, 55, 113-122. | 5.1 | 123 |
| 214 | Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?. Translational Gastroenterology and Hepatology, 2020, 5, 8-8. | 3.0 | 18 |
| 215 | Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. Journal of Geriatric Oncology, 2020, 11, 557-565. | 1.0 | 5 |
| 216 | Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. Journal of Hepatology, 2020, 72, 725-735. | 3.7 | 71 |
| 217 | When food regimes become hegemonic: Agrarian India through a Gramscian lens. Journal of Agrarian Change, 2020, 20, 188-206. | 1.8 | 8 |
| 218 | Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497. | 3.7 | 38 |
| 219 | Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. Molecular Cancer Therapeutics, 2020, 19, 384-396. | 4.1 | 18 |
| 220 | Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Review of Anticancer Therapy, 2020, 20, 63-74. | 2.4 | 14 |
| 221 | Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathology International, 2020, 70, 140-154. | 1.3 | 7 |
| 222 | XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Antiâ€“PD-1 Efficacy. Cancer Immunology Research, 2020, 8, 81-93. | 3.4 | 34 |
| 223 | TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HBâ€EGF Expression and Proteolytic Cleavage. Hepatology, 2020, 72, 923-939. | 7.3 | 36 |
| 224 | Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Frontiers of Medicine, 2020, 14, 273-283. | 3.4 | 9 |
| 225 | Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Letters, 2020, 473, 25-32. | 7.2 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 226 | Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with Î±-fetoprotein concentrations of at least 400â€‰ng/ml. Journal of Medical Economics, 2020, 23, 347-352. | 2.1 | 12 |
| 227 | Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 93-104. | 7.7 | 60 |
| 228 | Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. Acta Radiologica, 2020, 61, 983-991. | 1.1 | 9 |
| 229 | Harnessing big â€˜omicsâ€™ data and AI for drug discovery in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 238-251. | 17.8 | 90 |
| 230 | Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. Seminars in Liver Disease, 2020, 40, 131-142. | 3.6 | 3 |
| 231 | Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery, 2020, 15, 243-258. | 5.0 | 15 |
| 232 | Immunotherapy for hepatocellular carcinoma. Cancer Letters, 2020, 470, 8-17. | 7.2 | 169 |
| 233 | Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. Gut, 2020, 69, 1904-1906. | 12.1 | 24 |
| 234 | Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 78-89. | 3.7 | 71 |
| 235 | Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404. | 3.7 | 10 |
| 236 | Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treatment Reviews, 2020, 82, 101946. | 7.7 | 104 |
| 237 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202. | 1.6 | 1,255 |
| 238 | The chances of hepatic resection curing hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 711-717. | 3.7 | 41 |
| 239 | A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). Hpb, 2020, 22, 649-659. | 0.3 | 15 |
| 240 | Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Frontiers in Immunology, 2020, 11, 568759. | 4.8 | 79 |
| 241 | Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers, 2020, 12, 2859. | 3.7 | 92 |
| 242 | Downstaging to Liver Transplant. Clinics in Liver Disease, 2020, 24, 665-679. | 2.1 | 0 |
| 243 | The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188451. | 7.4 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 244 | The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2020, 132, 110797. | 5.6 | 35 |
| 245 | Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 755-769. | 2.1 | 9 |
| 246 | Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 567950. | 3.5 | 13 |
| 247 | Therapy of Primary Liver Cancer. Innovation(China), 2020, 1, 100032. | 9.1 | 46 |
| 248 | Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2020, 19, 153303382094748. | 1.9 | 3 |
| 249 | Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers, 2020, 12, 2730. | 3.7 | 24 |
| 250 | Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785. | 3.6 | 12 |
| 251 | Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943. | | 23 |
| 252 | Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Frontiers in Oncology, 2020, 10, 563249. | 2.8 | 18 |
| 253 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers, 2020, 12, 3025. | 3.7 | 55 |
| 254 | Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621. | 5.6 | 8 |
| 255 | Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 701-717. | 2.1 | 11 |
| 256 | Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. IScience, 2020, 23, 101580. | 4.1 | 22 |
| 257 | Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612. | 7.7 | 10 |
| 258 | Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines, 2020, 8, 616. | 4.4 | 47 |
| 259 | Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. JAMA Oncology, 2020, 6, e204930. | 7.1 | 124 |
| 260 | Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Current Medical Research and Opinion, 2020, 36, 1813-1823. | 1.9 | 0 |
| 261 | Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726. | | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 262 | Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. Vaccines, 2020, 8, 578. | 4.4 | 16 |
| 263 | Targeted Molecular Therapeutics for Bladder Cancerâ€"A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. International Journal of Molecular Sciences, 2020, 21, 7268. | 4.1 | 33 |
| 264 | Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Reports, 2020, 2, 100170. | 4.9 | 86 |
| 265 | Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1632. | 2.8 | 5 |
| 266 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564. | 7.1 | 746 |
| 267 | Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?. Clinical Liver Disease, 2020, 16, 96-100. | 2.1 | 0 |
| 268 | Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441. | 7.4 | 52 |
| 269 | Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience. Scandinavian Journal of Gastroenterology, 2020, 55, 1057-1062. | 1.5 | 15 |
| 270 | Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. Journal of Oncology, 2020, 2020, 1-4. | 1.3 | 1 |
| 271 | Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer, 2020, 9, 326-337. | 7.7 | 11 |
| 272 | Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862. | 3.7 | 47 |
| 273 | Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs, 2020, 80, 1203-1210. | 10.9 | 21 |
| 274 | Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report. Anticancer Research, 2020, 40, 4123-4129. | 1.1 | 9 |
| 275 | Immunotherapy in Gastrointestinal Cancers. Visceral Medicine, 2020, 36, 231-237. | 1.3 | 7 |
| 276 | Novel systemic therapy for hepatocellular carcinoma. Hepatology International, 2020, 14, 638-651. | 4.2 | 15 |
| 277 | Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Frontiers in Oncology, 2020, 10, 600233. | 2.8 | 10 |
| 278 | <p>Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 11725-11740. | 2.0 | 25 |
| 279 | Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435. | | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 280 | Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Molecular Therapy - Nucleic Acids, 2020, 22, 937-947. | 5.1 | 155 |
| 281 | Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2020, 21, 1097-1104. | 3.4 | 7 |
| 282 | Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058. | 2.8 | 5 |
| 283 | A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1253-1253. | 1.7 | 3 |
| 284 | High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39<sup>+</sup>CD8<sup>+</sup> T cells. Gut, 2021, 70, 1965-1977. | 12.1 | 72 |
| 285 | Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient . OncoTargets and Therapy, 2020, Volume 13, 12477-12487. | 2.0 | 9 |
| 286 | <p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 289-299. | 3.7 | 25 |
| 287 | Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 580241. | 2.8 | 31 |
| 288 | The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers, 2020, 12, 3285. | 3.7 | 85 |
| 289 | Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell and Bioscience, 2020, 10, 127. | 4.8 | 51 |
| 290 | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345. | 1.6 | 350 |
| 291 | Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397. | 3.7 | 17 |
| 292 | Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International, 2020, 14, 947-957. | 4.2 | 46 |
| 293 | Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Journal of Clinical Medicine, 2020, 9, 2533. | 2.4 | 15 |
| 294 | Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. Journal of Translational Medicine, 2020, 18, 306. | 4.4 | 88 |
| 295 | The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1017-1024. | 3.0 | 14 |
| 296 | 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2020, 9, 452-463. | 1.5 | 267 |
| 297 | Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514. | 6.5 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 298 | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 383, 693-695. | 27.0 | 16 |
| 299 | Effectiveness and Safety of Nivolumab in Childâ€“Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers, 2020, 12, 1968. | 3.7 | 40 |
| 300 | Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5232. | 4.1 | 7 |
| 301 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093761. | 3.2 | 78 |
| 302 | A new clinical prognostic nomogram for liver cancer based on immune score. PLoS ONE, 2020, 15, e0236622. | 2.5 | 7 |
| 303 | The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Frontiers in Immunology, 2020, 11, 1680. | 4.8 | 194 |
| 304 | Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers, 2020, 12, 2045. | 3.7 | 12 |
| 305 | Image-Guided Interventions in Oncology. , 2020, , . | | 1 |
| 306 | Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers, 2020, 12, 2132. | 3.7 | 18 |
| 307 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 2020, 38, 2960-2970. | 1.6 | 723 |
| 308 | Immuno-oncology for esophageal cancer. Future Oncology, 2020, 16, 2673-2681. | 2.4 | 16 |
| 309 | Targeting the immune milieu in gastrointestinal cancers. Journal of Gastroenterology, 2020, 55, 909-926. | 5.1 | 7 |
| 310 | Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integrative Cancer Therapies, 2020, 19, 153473542094258. | 2.0 | 8 |
| 311 | Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 146. | 17.1 | 320 |
| 312 | Different patterns of treatmentâ€related adverse events of programmed cell deathâ€1 and its ligandâ€1 inhibitors in different cancer types: A metaâ€analysis and systemic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e160-e178. | 1.1 | 6 |
| 313 | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Annals of Translational Medicine, 2020, 8, 1187-1187. | 1.7 | 31 |
| 314 | PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Frontiers in Immunology, 2020, 11, 589997. | 4.8 | 45 |
| 315 | Novel Therapies for Hepatocellular Carcinoma. Cancers, 2020, 12, 3049. | 3.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 316 | New advances in the diagnosis and management of hepatocellular carcinoma. BMJ, The, 2020, 371, m3544. | 6.0 | 210 |
| 317 | Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâ˜1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048. | 3.7 | 37 |
| 318 | Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Journal of Immunotherapy, 2020, 43, 291-298. | 2.4 | 7 |
| 319 | Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072. | | 45 |
| 320 | Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 6302. | 4.1 | 16 |
| 321 | Realâ€world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e249-e261. | 1.1 | 18 |
| 322 | Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut, 2020, 69, 2025-2034. | 12.1 | 77 |
| 323 | Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361. | 7.0 | 35 |
| 324 | Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells, 2020, 9, 1985. | 4.1 | 7 |
| 325 | Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Scientific Reports, 2020, 10, 14470. | 3.3 | 11 |
| 326 | Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. Liver Cancer, 2020, 9, 549-562. | 7.7 | 14 |
| 327 | Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 911-922. | 1.5 | 20 |
| 328 | New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control, 2020, 27, 107327482094597. | 1.8 | 15 |
| 329 | Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Medicine, 2020, 9, 7453-7459. | 2.8 | 11 |
| 330 | Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2020, 31, 1233-1241. | 0.5 | 11 |
| 331 | Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987. | | 70 |
| 332 | Seven immuneâ€related genes prognostic power and correlation with tumorâ€infiltrating immune cells in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 7440-7452. | 2.8 | 24 |
| 333 | Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current Oncology Reports, 2020, 22, 116. | 4.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 334 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714. | 4.5 | 51 |
| 335 | <p>Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 133-142. | 3.7 | 29 |
| 338 | Hepatocellular Carcinomaâ€“Circulating Tumor Cells Expressing PDâ€Ł1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatology Communications, 2020, 4, 1527-1540. | 4.3 | 60 |
| 339 | Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495. | 3.7 | 12 |
| 340 | <p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649. | 4.3 | 80 |
| 341 | Bromoâ€•and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Cancer Science, 2020, 111, 3503-3515. | 3.9 | 17 |
| 342 | Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094877. | 3.2 | 45 |
| 343 | Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Current HIV/AIDS Reports, 2020, 17, 547-556. | 3.1 | 21 |
| 344 | Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. American Journal of Gastroenterology, 2020, 115, 1960-1969. | 0.4 | 11 |
| 345 | <p>Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study</p>. OncoTargets and Therapy, 2020, Volume 13, 12683-12693. | 2.0 | 26 |
| 346 | Therapy in Advanced Hepatocellular Carcinoma. Seminars in Interventional Radiology, 2020, 37, 466-474. | 0.8 | 11 |
| 347 | Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. Clinical Medicine Insights: Oncology, 2020, 14, 117955492096877. | 1.3 | 1 |
| 348 | Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers, 2020, 12, 3830. | 3.7 | 47 |
| 349 | Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. Current Oncology, 2020, 27, 152-164. | 2.2 | 14 |
| 350 | Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Annals of Translational Medicine, 2020, 8, 1530-1530. | 1.7 | 0 |
| 351 | Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Research, 2020, 4, 191-198. | 1.4 | 8 |
| 352 | Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. Liver Research, 2020, 4, 180-190. | 1.4 | 6 |
| 353 | Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Communications, 2020, 40, 681-693. | 9.2 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 354 | CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5â€LSD1â€NFâ€ºB oncogenic signaling. Clinical and Translational Medicine, 2020, 10, e233. | 4.0 | 51 |
| 356 | <p>Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 337-345. | 3.7 | 6 |
| 357 | TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 575776. | 2.3 | 15 |
| 358 | Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Briefings in Bioinformatics, 2021, 22, . | 6.5 | 16 |
| 359 | Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877. | 4.8 | 133 |
| 360 | When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322. | | 26 |
| 361 | Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer, 2020, 9, 663-681. | 7.7 | 27 |
| 362 | Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 629-639. | 7.7 | 20 |
| 363 | Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma. Cancer Genomics and Proteomics, 2020, 17, 747-755. | 2.0 | 15 |
| 364 | The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 2020, 11, 568931. | 4.8 | 100 |
| 365 | New systemic agents for hepatocellular carcinoma: an update 2020. Current Opinion in Gastroenterology, 2020, 36, 177-183. | 2.3 | 17 |
| 366 | MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-Î±, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clinical Cancer Research, 2020, 26, 3936-3946. | 7.0 | 86 |
| 367 | New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702. | 14.4 | 53 |
| 368 | Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers, 2020, 12, 1221. | 3.7 | 46 |
| 369 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer, 2020, 9, 245-260. | 7.7 | 172 |
| 370 | Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Molecular Cancer, 2020, 19, 92. | 19.2 | 147 |
| 371 | Navigating the new landscape of secondâ€line treatment in advanced hepatocellular carcinoma. Liver International, 2020, 40, 1800-1811. | 3.9 | 33 |
| 372 | Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020, 26, 3979-3989. | 7.0 | 184 |

| # | Article | IF | Citations |
|---|---|---|---|
| 373 | Scientifically based combination therapies with immunoâ€oncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725. | 2.4 | 6 |
| 374 | FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 586. | 2.8 | 42 |
| 375 | Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. Hematological Oncology, 2020, 38, 565-575. | 1.7 | 22 |
| 376 | Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology and Oncology, 2020, 13, 47. | 17.0 | 84 |
| 377 | Atezolizumab plus Bevacizumab â€" A Landmark in Liver Cancer. New England Journal of Medicine, 2020, 382, 1953-1955. | 27.0 | 44 |
| 378 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncology, The, 2020, 21, 808-820. | 10.7 | 371 |
| 379 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905. | 27.0 | 3,828 |
| 380 | Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Review of Clinical Pharmacology, 2020, 13, 623-629. | 3.1 | 8 |
| 381 | Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404. | | 29 |
| 382 | Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Experimental Hematology and Oncology, 2020, 9, 10. | 5.0 | 48 |
| 383 | ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. , 2020, 8, e000340. | | 124 |
| 384 | Antiâ€"PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infectionâ€"Related Advanced Hepatocellular Carcinoma: A Literature Review. Frontiers in Immunology, 2020, 11, 1037. | 4.8 | 55 |
| 385 | Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells. Nano Letters, 2020, 20, 5133-5140. | 9.1 | 19 |
| 386 | The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas. Clinical Cancer Research, 2020, 26, 4947-4957. | 7.0 | 24 |
| 387 | Is the era of sorafenib over? A review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092760. | 3.2 | 45 |
| 388 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536. | 2.4 | 50 |
| 389 | Ulcerative esophagitis associated with combined nivolumab and ipilimumab therapy. Journal of Dermatology, 2020, 47, e299-e300. | 1.2 | 7 |
| 390 | Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells, 2020, 9, 1370. | 4.1 | 256 |

| # | Article | IF | Citations |
|---|---|---|---|
| 391 | Finding the hot spot: identifying immune sensitive gastrointestinal tumors. Translational Gastroenterology and Hepatology, 2020, 5, 48-48. | 3.0 | 6 |
| 392 | Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression, 2020, 20, 53-65. | 1.2 | 65 |
| 393 | Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665. | | 8 |
| 394 | Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. Lung Cancer, 2020, 146, 145-153. | 2.0 | 14 |
| 395 | Advances in immunotherapy for colorectal cancer: a review. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482091752. | 3.2 | 139 |
| 396 | Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Current Oncology Reports, 2020, 22, 70. | 4.0 | 11 |
| 397 | Cautious Optimismâ€"The Current Role of Immunotherapy in Gastrointestinal Cancers. Current Oncology, 2020, 27, 59-68. | 2.2 | 4 |
| 398 | Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. Oncologist, 2020, 25, e946-e954. | 3.7 | 3 |
| 399 | Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. Hepatobiliary Surgery and Nutrition, 2020, 9, 348-349. | 1.5 | 1 |
| 400 | Immune-based therapies for hepatocellular carcinoma. Oncogene, 2020, 39, 3620-3637. | 5.9 | 154 |
| 401 | Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes and Diseases, 2020, 7, 359-369. | 3.4 | 40 |
| 402 | Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. Translational Gastroenterology and Hepatology, 2020, 5, 21-21. | 3.0 | 2 |
| 403 | N6-methyladenosine (m6A) RNA methylation regulators are associated with clinical prognosis in hepatocellular carcinoma. Translational Cancer Research, 2020, 9, 323-334. | 1.0 | 2 |
| 404 | Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes and Diseases, 2020, 7, 320-327. | 3.4 | 10 |
| 405 | The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 174-185. | 3.8 | 13 |
| 406 | Systemic therapy in advanced-stage hepatocellular carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 212-217. | 0.5 | 1 |
| 407 | Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 775. | 3.7 | 70 |
| 408 | Nivolumab for the treatment of hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 687-693. | 3.1 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 409 | Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 55. | 2.3 | 14 |
| 410 | Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 4298-4311. | 3.6 | 27 |
| 411 | Management of hepatitis B in the era of checkpoint inhibition. , 2020, 8, e000276. | | 2 |
| 412 | Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. Hepatobiliary Surgery and Nutrition, 2020, 9, 86-88. | 1.5 | 1 |
| 413 | Regorafenib Versus Nivolumab After Sorafenib Failure: Realâ€World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications, 2020, 4, 1073-1086. | 4.3 | 28 |
| 414 | Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 91-99. | 3.7 | 7 |
| 415 | Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Frontiers in Oncology, 2020, 10, 1043. | 2.8 | 29 |
| 416 | Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. Lung Cancer, 2020, 147, 21-25. | 2.0 | 10 |
| 417 | Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093518. | 3.2 | 6 |
| 418 | Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma. Hepatology Research, 2020, 50, 978-984. | 3.4 | 7 |
| 419 | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663. | 3.7 | 112 |
| 420 | Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668. | 3.7 | 54 |
| 421 | Metaâ€analysis of immuneâ€related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thoracic Cancer, 2020, 11, 2406-2430. | 1.9 | 40 |
| 422 | Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepatic Oncology, 2020, 7, HEP20. | 4.2 | 30 |
| 423 | Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188391. | 7.4 | 96 |
| 424 | Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma. Pathology and Oncology Research, 2020, 26, 2587-2595. | 1.9 | 4 |
| 425 | Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57. | 9.6 | 104 |
| 426 | Pembrolizumab for the treatment of esophageal cancer. Expert Opinion on Biological Therapy, 2020, 20, 1143-1150. | 3.1 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 428 | <p>Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World</p>. OncoTargets and Therapy, 2020, Volume 13, 143-149. | 2.0 | 15 |
| 429 | The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP17. | 4.2 | 46 |
| 430 | Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response. Pharmaceuticals, 2020, 13, 26. | 3.8 | 1 |
| 431 | A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020, 122, 963-970. | 6.4 | 17 |
| 432 | DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 601-607. | 3.1 | 28 |
| 433 | Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 571-580. | 10.7 | 373 |
| 434 | Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481. | 10.7 | 29 |
| 435 | Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. Scientific Reports, 2020, 10, 3392. | 3.3 | 46 |
| 436 | <p>The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma</p>. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 11-17. | 3.7 | 64 |
| 437 | Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Science Reports, 2020, 3, e147. | 1.5 | 4 |
| 438 | Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transplantation, 2020, 26, 823-831. | 2.4 | 25 |
| 439 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOSâ€“ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Annals of Oncology, 2020, 31, 334-351. | 1.2 | 138 |
| 440 | Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Cancer Letters, 2020, 476, 120-128. | 7.2 | 17 |
| 441 | Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142. | 0.7 | 13 |
| 442 | Current status of immunotherapy in gastrointestinal malignancies. Zeitschrift Fur Gastroenterologie, 2020, 58, 542-555. | 0.5 | 5 |
| 444 | Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine, 2020, 53, 102659. | 6.1 | 48 |
| 445 | Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer, 2020, 145, 181-185. | 2.0 | 36 |
| 446 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319. | 3.7 | 310 |

| # | Article | IF | Citations |
|---|---|---|---|
| 447 | Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules, 2020, 10, 117. | 4.0 | 39 |
| 448 | Hepatocellular Carcinomaâ€"How to Determine Therapeutic Options. Hepatology Communications, 2020, 4, 342-354. | 4.3 | 14 |
| 449 | Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229. | 3.7 | 311 |
| 450 | mRECIST for HCC: Performance and novel refinements. Journal of Hepatology, 2020, 72, 288-306. | 3.7 | 292 |
| 451 | Novel patient-derived preclinical models of liver cancer. Journal of Hepatology, 2020, 72, 239-249. | 3.7 | 41 |
| 452 | Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 320-341. | 3.7 | 165 |
| 453 | Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 2020, 72, 209-214. | 3.7 | 39 |
| 454 | Molecular therapies for HCC: Looking outside the box. Journal of Hepatology, 2020, 72, 342-352. | 3.7 | 250 |
| 455 | Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers, 2020, 12, 182. | 3.7 | 74 |
| 456 | Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. Medicine (United States), 2020, 99, e19013. | 1.0 | 64 |
| 457 | Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126. | 3.6 | 15 |
| 458 | Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer, 2020, 9, 426-439. | 7.7 | 26 |
| 459 | Emerging biomarkers in HCC patients: Current status. International Journal of Surgery, 2020, 82, 70-76. | 2.7 | 36 |
| 460 | Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 2020, 12, 1089. | 3.7 | 119 |
| 461 | IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989. | 2.4 | 136 |
| 462 | Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 2020, 12, 738. | 3.7 | 826 |
| 463 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285. | 3.7 | 14 |
| 464 | Immunotherapy in hepatocellular carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 218-222. | 0.5 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 465 | The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 2020, 86, 102011. | 7.7 | 31 |
| 466 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Frontiers in Immunology, 2020, 11, 508. | 4.8 | 58 |
| 467 | Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 5276-5286. | 7.0 | 13 |
| 468 | Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clinical Liver Disease, 2020, 15, 53-58. | 2.1 | 23 |
| 469 | Necroptosis in Cholangiocarcinoma. Cells, 2020, 9, 982. | 4.1 | 13 |
| 470 | Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. CardioVascular and Interventional Radiology, 2020, 43, 1175-1181. | 2.0 | 12 |
| 471 | Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 230-230. | 1.7 | 15 |
| 472 | Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 845-854. | 1.5 | 2 |
| 473 | Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. , 2020, 8, e000394. | | 39 |
| 474 | A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2020, 9, 119-137. | 7.7 | 45 |
| 475 | Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29. | 17.0 | 146 |
| 476 | Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. International Journal of Molecular Sciences, 2020, 21, 2286. | 4.1 | 61 |
| 477 | The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. Journal of the National Cancer Institute, 2021, 113, 27-37. | 6.3 | 17 |
| 478 | Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. European Journal of Surgical Oncology, 2021, 47, 583-590. | 1.0 | 7 |
| 479 | Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. Chinese Clinical Oncology, 2021, 10, 10-10. | 1.2 | 10 |
| 480 | Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. Tumori, 2021, 107, 32-38. | 1.1 | 4 |
| 481 | Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology, 2021, 73, 150-157. | 7.3 | 70 |
| 482 | Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. Visceral Medicine, 2021, 37, 87-93. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 483 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191. | 7.3 | 235 |
| 484 | The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology, 2021, 73, 75-85. | 7.3 | 100 |
| 485 | Liver Cancer Immunity. Hepatology, 2021, 73, 86-103. | 7.3 | 52 |
| 486 | Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127. | 7.3 | 104 |
| 487 | Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome. Case Reports in Oncology, 2021, 13, 1252-1257. | 0.7 | 8 |
| 488 | FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clinical Cancer Research, 2021, 27, 1836-1841. | 7.0 | 102 |
| 489 | Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359. | 3.7 | 122 |
| 490 | Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut, 2021, 70, 204-214. | 12.1 | 150 |
| 491 | Targeting Tumorâ€Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology, 2021, 73, 821-832. | 7.3 | 25 |
| 492 | Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology, 2021, 73, 104-114. | 7.3 | 54 |
| 493 | Transcriptome Profiling Identifies TIGIT as a Marker of Tâ€Cell Exhaustion in Liver Cancer. Hepatology, 2021, 73, 1399-1418. | 7.3 | 61 |
| 494 | Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833. | 5.5 | 6 |
| 495 | Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clinical Cancer Research, 2021, 27, 1003-1011. | 7.0 | 334 |
| 496 | The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. JAMA Oncology, 2021, 7, 113. | 7.1 | 213 |
| 497 | Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151. | 5.9 | 77 |
| 498 | Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718. | 7.0 | 27 |
| 499 | Hepatitis C virus associated hepatocellular carcinoma. Advances in Cancer Research, 2021, 149, 103-142. | 5.0 | 18 |
| 500 | Systemic treatment of HCC in special populations. Journal of Hepatology, 2021, 74, 931-943. | 3.7 | 72 |

| # | Article | IF | Citations |
|---|---|---|---|
| 501 | Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715. | 3.7 | 60 |
| 502 | Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 62-75. | 2.6 | 7 |
| 503 | Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167. | 4.4 | 30 |
| 504 | Hepatocellular carcinoma: Clinicopathologic associations amidst marked phenotypic heterogeneity. Pathology Research and Practice, 2021, 217, 153290. | 2.3 | 2 |
| 505 | Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127. | 10.5 | 159 |
| 506 | A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Critical Reviews in Oncology/Hematology, 2021, 157, 103173. | 4.4 | 12 |
| 507 | Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 423-433. | 2.5 | 1 |
| 508 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International, 2021, 41, 598-607. | 3.9 | 13 |
| 509 | Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. American Journal of Health-System Pharmacy, 2021, 78, 187-202. | 1.0 | 9 |
| 510 | The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160. | 4.4 | 26 |
| 511 | Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874. | 4.1 | 20 |
| 512 | Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2021, 120, 1051-1060. | 1.7 | 72 |
| 513 | Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 739-762. | 4.5 | 29 |
| 514 | The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, 26, e1036-e1049. | 3.7 | 30 |
| 515 | Transarterial chemoembolisation enhances programmed deathâ€1 and programmed deathâ€ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79, 36-46. | 2.9 | 49 |
| 516 | Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell, 2021, 184, 404-421.e16. | 28.9 | 399 |
| 517 | Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 28-33. | 1.3 | 5 |
| 518 | Qualification of tumour mutational burden by targeted nextâ€generation sequencing as a biomarker in hepatocellular carcinoma. Liver International, 2021, 41, 192-203. | 3.9 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 519 | Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 123-136. | 6.3 | 28 |
| 520 | Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Antiâ€“Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transplantation, 2021, 27, 444-449. | 2.4 | 24 |
| 521 | Recurrence of hepatocellular carcinoma following liver transplantation. Expert Review of Gastroenterology and Hepatology, 2021, 15, 91-102. | 3.0 | 21 |
| 522 | Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Gut Microbes, 2021, 13, 1-21. | 9.8 | 33 |
| 523 | Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics, 2021, 11, 5955-5969. | 10.0 | 23 |
| 524 | TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 443-464. | 4.5 | 43 |
| 525 | Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunology, Immunotherapy, 2021, 70, 1929-1937. | 4.2 | 19 |
| 526 | The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. Cancer Management and Research, 2021, Volume 13, 757-764. | 1.9 | 0 |
| 527 | Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36. | 3.8 | 30 |
| 528 | Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer, 2021, 10, 360-369. | 7.7 | 25 |
| 529 | Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180. | 3.2 | 10 |
| 530 | Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110109. | 3.2 | 15 |
| 531 | Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Annals of Surgical Oncology, 2021, 28, 1499-1510. | 1.5 | 3 |
| 532 | Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2033761. | 5.9 | 27 |
| 533 | Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nature Communications, 2021, 12, 227. | 12.8 | 76 |
| 534 | Systemic therapy of liver cancer. Advances in Cancer Research, 2021, 149, 257-294. | 5.0 | 44 |
| 535 | Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110169. | 3.2 | 74 |
| 536 | Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311. | 3.2 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 537 | Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. Aging, 2021, 13, 3969-3993. | 3.1 | 7 |
| 538 | Immunotherapy in hepatocellular cancer. Advances in Cancer Research, 2021, 149, 295-320. | 5.0 | 0 |
| 539 | Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 574778. | 2.8 | 4 |
| 540 | Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Frontiers in Immunology, 2020, 11, 613946. | 4.8 | 40 |
| 541 | Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 1958-1966. | 2.1 | 6 |
| 542 | Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clinical and Molecular Hepatology, 2021, 27, 144-156. | 8.9 | 19 |
| 543 | Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110027. | 3.2 | 91 |
| 544 | ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399. | 3.2 | 7 |
| 545 | Perspectives of Radiotherapy in Immuno-oncology Era. , 2021, , 325-337. | | 0 |
| 546 | Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 132-139. | 2.4 | 19 |
| 547 | Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular CarcinomasFondamentaux de lâ€™immunologie des Cancers Digestifs (Gastriques et HÃ©patocellulaires). Oncologie, 2021, 23, 47-59. | 0.7 | 5 |
| 548 | Advanced drug delivery systems in liver cancer. , 2021, , 217-223. | | 1 |
| 549 | Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. , 2021, , 123-141. | | 0 |
| 550 | Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies. Digestive Disease Interventions, 2021, 05, 022-031. | 0.2 | 4 |
| 551 | Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110381. | 1.9 | 2 |
| 552 | The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Cancers, 2021, 13, 238. | 3.7 | 14 |
| 553 | LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 217-223. | 2.5 | 30 |
| 554 | A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma. BMC Medical Genomics, 2021, 14, 49. | 1.5 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 555 | Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, e266-e277. | 2.9 | 12 |
| 556 | Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 618206. | 2.8 | 53 |
| 557 | The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. Targeted Oncology, 2021, 16, 153-163. | 3.6 | 5 |
| 558 | Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 75. | 17.1 | 323 |
| 559 | Clinical outcomes and influencing factors of PDâ€'1/PDâ€'L1 in hepatocellular carcinoma (Review). Oncology Letters, 2021, 21, 279. | 1.8 | 36 |
| 560 | Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies. Journal of the Chinese Medical Association, 2021, 84, 121-122. | 1.4 | 2 |
| 561 | Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Current Hepatology Reports, 2021, 20, 23-33. | 0.9 | 10 |
| 562 | The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. International Journal of Molecular Sciences, 2021, 22, 1931. | 4.1 | 31 |
| 563 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362. | 27.6 | 646 |
| 564 | Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers, 2021, 13, 584. | 3.7 | 6 |
| 565 | Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell International, 2021, 21, 98. | 4.1 | 46 |
| 566 | PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. Journal of Clinical Investigation, 2021, 131, . | 8.2 | 51 |
| 567 | Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484. | 2.6 | 20 |
| 568 | Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. , 2021, 9, e001945. | | 74 |
| 569 | First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2021, 13, 931. | 3.7 | 26 |
| 570 | Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers, 2021, 13, 651. | 3.7 | 7 |
| 571 | Sequencing Treatments in Hepatocellular Carcinoma: Will Value Frameworks Provide a Solution?. JCO Oncology Practice, 2021, 17, 164-166. | 2.9 | 3 |
| 572 | Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286. | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 573 | Cellular heterogeneity and plasticity in liver cancer. Seminars in Cancer Biology, 2022, 82, 134-149. | 9.6 | 58 |
| 574 | The Roles of circRNAs in Liver Cancer Immunity. Frontiers in Oncology, 2020, 10, 598464. | 2.8 | 13 |
| 575 | Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation. Npj Precision Oncology, 2021, 5, 27. | 5.4 | 11 |
| 576 | Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions, 2021, 05, 277-282. | 0.2 | 0 |
| 577 | Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nature Communications, 2021, 12, 1455. | 12.8 | 96 |
| 578 | Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Frontiers in Oncology, 2021, 11, 650481. | 2.8 | 23 |
| 579 | A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 43 |
| 580 | Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652172. | 4.8 | 21 |
| 581 | Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522. | 3.7 | 18 |
| 582 | Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101590. | 1.5 | 17 |
| 583 | Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. Frontiers in Molecular Biosciences, 2021, 8, 602227. | 3.5 | 3 |
| 584 | Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. Medicine (United States), 2021, 100, e24683. | 1.0 | 7 |
| 585 | Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Frontiers in Immunology, 2021, 12, 655697. | 4.8 | 126 |
| 586 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456. | 27.8 | 649 |
| 587 | Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 1.4 | 5 |
| 588 | CD8+ T Cell Responses during HCV Infection and HCC. Journal of Clinical Medicine, 2021, 10, 991. | 2.4 | 22 |
| 589 | Programmed cell deathâ€ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2601-2609. | 2.8 | 5 |
| 590 | Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652007. | 4.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 591 | Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664. | | 11 |
| 592 | The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 626984. | 2.8 | 12 |
| 593 | Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterology, 2021, 67, . | 0.5 | 7 |
| 594 | Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. Oncologist, 2021, 26, e827-e830. | 3.7 | 9 |
| 595 | Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. Journal of Medical Case Reports, 2021, 15, 132. | 0.8 | 7 |
| 596 | Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. Expert Review of Gastroenterology and Hepatology, 2021, 15, 589-598. | 3.0 | 17 |
| 597 | Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiotherapy and Oncology, 2021, 156, 120-126. | 0.6 | 19 |
| 598 | Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS Journal, 2021, 23, 39. | 4.4 | 356 |
| 599 | PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer, 2021, 21, 301. | 2.6 | 42 |
| 600 | Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. Hepatology International, 2021, 15, 287-289. | 4.2 | 2 |
| 601 | How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals, 2021, 14, 233. | 3.8 | 9 |
| 602 | Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 1.4 | 5 |
| 603 | The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 177-191. | 3.7 | 9 |
| 604 | Immune Checkpoint Inhibitors in the Treatment of Cancer. Current Clinical Pharmacology, 2022, 17, 103-113. | 0.6 | 18 |
| 605 | Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging, 2021, 13, 11257-11280. | 3.1 | 11 |
| 606 | Predictive Factors for the Effectiveness of Repeated Lines of Transarterial Chemoembolization in the Treatment of Localized Hepatocellular Carcinoma. Journal of Oncology Diagnostic Radiology and Radiotherapy, 2021, 4, 42-52. | 0.2 | 0 |
| 607 | Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 190-199. | 6.4 | 26 |
| 608 | Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences, 2021, 8, 635243. | 3.5 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 609 | Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer, 2021, 21, 425. | 2.6 | 16 |
| 610 | Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 562315. | 2.8 | 38 |
| 611 | Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers, 2021, 13, 1729. | 3.7 | 14 |
| 612 | Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma. Molecular Medicine, 2021, 27, 36. | 4.4 | 7 |
| 613 | Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 2164. | 3.7 | 14 |
| 614 | Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?. Hepatobiliary Surgery and Nutrition, 2021, 10, 180-192. | 1.5 | 47 |
| 615 | Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer, 2021, 10, 249-259. | 7.7 | 49 |
| 616 | Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer, 2021, 10, 296-308. | 7.7 | 63 |
| 617 | miR-4456/CCL3/CCR5 Pathway in the Pathogenesis of Tight Junction Impairment in Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology, 2021, 12, 551839. | 3.5 | 6 |
| 618 | Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting. Current Drug Targets, 2021, 22, 779-792. | 2.1 | 13 |
| 619 | Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543. | 17.8 | 609 |
| 620 | Î²-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers, 2021, 13, 1830. | 3.7 | 16 |
| 621 | Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Frontiers in Immunology, 2021, 12, 643310. | 4.8 | 27 |
| 622 | Repeated transarterial chemoembolization with epirubicinâ€loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Molecular and Clinical Oncology, 2021, 14, 119. | 1.0 | 1 |
| 623 | Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology, Immunotherapy, 2021, 70, 3207-3216. | 4.2 | 21 |
| 624 | Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplantation Reviews, 2021, 35, 100606. | 2.9 | 6 |
| 625 | The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers, 2021, 13, 1962. | 3.7 | 40 |
| 626 | NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239. | 3.7 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 627 | Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Frontiers in Immunology, 2021, 12, 642958. | 4.8 | 12 |
| 628 | AB4 inhibits Notch signaling and promotes cancer cell apoptosis in liver cancer. Oncology Reports, 2021, 45, . | 2.6 | 1 |
| 629 | Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Annals of Translational Medicine, 2021, 9, 652-652. | 1.7 | 22 |
| 630 | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284. | 7.7 | 29 |
| 631 | The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Current Opinion in Oncology, 2021, 33, 386-394. | 2.4 | 13 |
| 632 | A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 2021, 13, . | 12.4 | 59 |
| 633 | Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers, 2021, 13, 1922. | 3.7 | 29 |
| 634 | Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist, 2021, 26, e1216-e1225. | 3.7 | 26 |
| 635 | Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Metaâ€Analysis. Frontiers in Oncology, 2021, 11, 650292. | 2.8 | 22 |
| 636 | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kongâ€”A Territory-Wide Cohort Study. Cancers, 2021, 13, 2002. | 3.7 | 8 |
| 637 | Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers, 2021, 13, 1949. | 3.7 | 31 |
| 638 | Combined Inhibition of TGF-Î²1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. Journal of Clinical Medicine, 2021, 10, 1889. | 2.4 | 25 |
| 639 | Impact of the microbiome on tumor immunity. Current Opinion in Immunology, 2021, 69, 39-46. | 5.5 | 9 |
| 640 | Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Panminerva Medica, 2021, , . | 0.8 | 2 |
| 641 | Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry, 2021, 28, 3107-3146. | 2.4 | 9 |
| 642 | Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Design, Development and Therapy, 2021, Volume 15, 1873-1882. | 4.3 | 20 |
| 644 | Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental and Clinical Cancer Research, 2021, 40, 172. | 8.6 | 104 |
| 645 | Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Frontiers in Oncology, 2021, 11, 559161. | 2.8 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 646 | Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. Cancers, 2021, 13, 2708. | 3.7 | 19 |
| 647 | Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells, 2021, 10, 1332. | 4.1 | 24 |
| 648 | Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Frontiers in Oncology, 2021, 11, 683341. | 2.8 | 13 |
| 649 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208. | 6.4 | 22 |
| 650 | Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer, 2021, 21, 569. | 2.6 | 17 |
| 651 | Kinetics of the neutrophilâ€lymphocyte ratio during PDâ€1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver International, 2021, 41, 2189-2199. | 3.9 | 26 |
| 652 | The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines, 2021, 9, 532. | 4.4 | 65 |
| 653 | Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. Cancers, 2021, 13, 2543. | 3.7 | 4 |
| 654 | Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. International Immunopharmacology, 2021, 94, 107467. | 3.8 | 18 |
| 655 | Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma. Journal of Biomedical Nanotechnology, 2021, 17, 771-792. | 1.1 | 1 |
| 656 | Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 477-492. | 3.7 | 15 |
| 657 | Immuneâ€related adverse events predict responses to <scp>PD</scp>â€1 blockade immunotherapy in hepatocellular carcinoma. International Journal of Cancer, 2021, 149, 959-966. | 5.1 | 15 |
| 658 | Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 387-401. | 3.7 | 62 |
| 660 | Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs. Anticancer Research, 2021, 41, 2569-2573. | 1.1 | 2 |
| 661 | Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 3625-3633. | 2.1 | 5 |
| 662 | Tâ€cell mediated responses against alphaâ€fœtoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patientsâ€™ survival. Liver Cancer International, 2021, 2, 7-14. | 1.3 | 0 |
| 663 | The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552. | 4.4 | 20 |
| 664 | Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 2434-2457. | 3.3 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 665 | Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open, 2021, 5, 705-711. | 1.6 | 2 |
| 666 | Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences, 2021, 22, 5801. | 4.1 | 182 |
| 667 | Systemic Therapy for Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 337-340. | 2.1 | 5 |
| 668 | The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS ONE, 2021, 16, e0249426. | 2.5 | 11 |
| 669 | Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 686621. | 2.8 | 28 |
| 670 | The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers, 2021, 13, 2651. | 3.7 | 18 |
| 671 | Immunotherapy for GI Cancers. Advances in Oncology, 2021, 1, 283-295. | 0.2 | 0 |
| 672 | Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141. | 3.6 | 10 |
| 673 | Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 1.4 | 4 |
| 674 | In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486. | 4.8 | 26 |
| 675 | Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Review of Anticancer Therapy, 2021, 21, 621-628. | 2.4 | 11 |
| 676 | Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 25-38. | 4.2 | 15 |
| 677 | Histopathology of Gastrointestinal Immune-related Adverse Events. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, e15-e26. | 3.7 | 7 |
| 678 | Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina ClÃnica (English Edition), 2021, 156, 463.e1-463.e30. | 0.2 | 16 |
| 679 | Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Global Oncology, 2021, 7, 756-766. | 1.8 | 25 |
| 680 | Cellular based treatment modalities for unresectable hepatocellular carcinoma. World Journal of Clinical Oncology, 2021, 12, 290-308. | 2.3 | 4 |
| 681 | Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 507-512. | 3.7 | 8 |
| 682 | Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 346-359. | 7.7 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 683 | The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101664. | 1.5 | 9 |
| 684 | Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223. | 7.7 | 307 |
| 685 | PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123. | 4.1 | 61 |
| 686 | A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer, 2021, 10, 500-509. | 7.7 | 9 |
| 687 | Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. Expert Opinion on Investigational Drugs, 2021, 30, 827-835. | 4.1 | 3 |
| 688 | Exploring liver cancer biology through functional genetic screens. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 690-704. | 17.8 | 31 |
| 689 | Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs and Aging, 2021, 38, 579-591. | 2.7 | 5 |
| 690 | Editorial: Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 698515. | 2.8 | 0 |
| 691 | Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver International, 2021, 41, 2759-2767. | 3.9 | 5 |
| 692 | Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discovery Today, 2021, 26, 1539-1546. | 6.4 | 18 |
| 693 | Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy, 2021, 13, 637-644. | 2.0 | 63 |
| 694 | Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokineticsÂand future treatment strategies. Future Oncology, 2021, 17, 2243-2256. | 2.4 | 36 |
| 695 | Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Current Oncology, 2021, 28, 2150-2172. | 2.2 | 9 |
| 696 | Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?. World Journal of Gastroenterology, 2021, 27, 3429-3439. | 3.3 | 4 |
| 697 | Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 2662. | 2.4 | 13 |
| 698 | The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428. | 2.8 | 32 |
| 699 | Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. Clinical and Experimental Medicine, 2022, 22, 65-74. | 3.6 | 41 |
| 700 | Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Bioscience Reports, 2021, 41, . | 2.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 701 | <scp>FDA</scp> Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist, 2021, 26, 797-806. | 3.7 | 61 |
| 702 | An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Frontiers in Pharmacology, 2021, 12, 707930. | 3.5 | 12 |
| 703 | Characterization of response to atezolizumabÂ+Âbevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. Cancer Medicine, 2021, 10, 5437-5447. | 2.8 | 29 |
| 704 | International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584. | 1.3 | 91 |
| 705 | The TGF-Î² Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers, 2021, 13, 3248. | 3.7 | 37 |
| 706 | Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276. | 3.6 | 14 |
| 707 | USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 201. | 8.6 | 27 |
| 708 | Prospects and Challenges for T Cell-Based Therapies of HCC. Cells, 2021, 10, 1651. | 4.1 | 13 |
| 709 | Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs, 2022, 31, 371-378. | 4.1 | 65 |
| 710 | Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009. | 3.3 | 103 |
| 711 | Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncology Practice, 2022, 18, 35-41. | 2.9 | 12 |
| 712 | Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World Journal of Gastroenterology, 2021, 27, 4104-4142. | 3.3 | 15 |
| 713 | Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768. | 0.8 | 9 |
| 714 | Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World Journal of Clinical Cases, 2021, 9, 5988-5998. | 0.8 | 2 |
| 715 | Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 691410. | 3.7 | 13 |
| 716 | Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 2021, 98, 102221. | 7.7 | 43 |
| 717 | Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Journal of Clinical Medicine, 2021, 10, 3201. | 2.4 | 13 |
| 718 | Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Frontiers in Oncology, 2021, 11, 684867. | 2.8 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 719 | How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers, 2021, 13, 3536. | 3.7 | 4 |
| 720 | Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. Current Oncology Reports, 2021, 23, 100. | 4.0 | 26 |
| 721 | Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103376. | 4.4 | 9 |
| 722 | Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. JCO Oncology Practice, 2021, , OP.21.00451. | 2.9 | 0 |
| 723 | Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Review of Clinical Pharmacology, 2021, 14, 1353-1365. | 3.1 | 6 |
| 724 | Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. International Journal of Molecular Sciences, 2021, 22, 7800. | 4.1 | 26 |
| 725 | Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 511-520. | 1.3 | 29 |
| 726 | The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1195-1210. | 2.5 | 8 |
| 727 | Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. Journal of Gastrointestinal Oncology, 2021, 12, S361-S373. | 1.4 | 66 |
| 728 | Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 690151. | 3.5 | 28 |
| 729 | On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 2021, 13, 3758. | 3.7 | 8 |
| 730 | Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653. | 1.9 | 11 |
| 731 | The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells, 2021, 10, 1909. | 4.1 | 6 |
| 732 | Current cancer therapies and their influence on glucose control. World Journal of Diabetes, 2021, 12, 1010-1025. | 3.5 | 10 |
| 733 | Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896. | 2.8 | 23 |
| 734 | Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2â€“3 study. Lancet Oncology, The, 2021, 22, 977-990. | 10.7 | 459 |
| 735 | How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. Annals of Oncology, 2021, 32, 833-836. | 1.2 | 21 |
| 736 | Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. Anti-Cancer Drugs, 2021, Publish Ahead of Print, . | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 737 | Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer, 2021, 21, 775. | 2.6 | 28 |
| 738 | Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?. Expert Opinion on Investigational Drugs, 2021, , 1-3. | 4.1 | 1 |
| 739 | An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822. | 3.7 | 17 |
| 740 | Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824. | 2.8 | 7 |
| 741 | Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799. | 3.7 | 52 |
| 742 | Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as firstâ€line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer, 2021, 127, 3782-3793. | 4.1 | 82 |
| 743 | Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132. | | 17 |
| 744 | Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Translational Oncology, 2021, 14, 101116. | 3.7 | 8 |
| 745 | Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3517-3534. | 2.5 | 5 |
| 746 | Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. Journal of Interventional Medicine, 2021, 4, 105-113. | 0.5 | 7 |
| 747 | Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers, 2021, 13, 4334. | 3.7 | 20 |
| 748 | The State of Immunotherapy in Hepatobiliary Cancers. Cells, 2021, 10, 2096. | 4.1 | 18 |
| 749 | PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 887-897. | 3.7 | 17 |
| 750 | First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1245-1251. | 3.0 | 75 |
| 751 | Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2115-2125. | 2.5 | 55 |
| 752 | Using cell-free DNA for HCC surveillance and prognosis. JHEP Reports, 2021, 3, 100304. | 4.9 | 27 |
| 753 | Comprehensive Analyses of the Infiltrating Immune Cell Landscape and Its Clinical Significance in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 4695-4704. | 1.8 | 7 |
| 754 | Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Clinical Drug Investigation, 2021, 41, 795-808. | 2.2 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 755 | Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers, 2021, 13, 4387. | 3.7 | 15 |
| 756 | Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research, 2021, 9, 64. | 6.8 | 13 |
| 757 | Changes in Wnt and TGF-Î² Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Frontiers in Cell and Developmental Biology, 2021, 9, 639779. | 3.7 | 27 |
| 758 | Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surgery and Nutrition, 2021, 10, 434-442. | 1.5 | 28 |
| 759 | Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitorâ€"Related Esophagitis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 896-904. | 4.9 | 13 |
| 760 | Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Reports, 2021, 3, 100318. | 4.9 | 5 |
| 761 | Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Frontiers in Oncology, 2021, 11, 650394. | 2.8 | 16 |
| 762 | Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World Journal of Gastrointestinal Oncology, 2021, 13, 772-798. | 2.0 | 11 |
| 763 | Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy. Journal of Clinical and Translational Hepatology, 2022, 10, 147-158. | 1.4 | 21 |
| 764 | Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. Journal of Cellular and Molecular Medicine, 2021, 25, 8602-8614. | 3.6 | 15 |
| 765 | Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 845-855. | 2.0 | 10 |
| 766 | Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000. | 1.4 | 4 |
| 767 | Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 615-628. | 7.7 | 31 |
| 768 | A Molecular Hepatocellular Carcinoma Prognostic Score System Precisely Predicts Overall Survival of Hepatocellular Carcinoma Patients. Journal of Clinical and Translational Hepatology, 2022, 10, 273-283. | 1.4 | 3 |
| 769 | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Frontiers in Immunology, 2021, 12, 712351. | 4.8 | 5 |
| 770 | Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 708819. | 3.7 | 4 |
| 771 | KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. International Journal of Biochemistry and Cell Biology, 2021, 137, 106037. | 2.8 | 3 |
| 772 | Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 927-939. | 2.4 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 773 | Recent advances and applications of microspheres and nanoparticles in transarterial chemoembolization for hepatocellular carcinoma. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1749. | 6.1 | 15 |
| 774 | Antitumor and off-target effects of cholesterol-conjugated let-7a mimics in an orthotopic hepatocellular carcinoma xenograft nude mouse model. Journal of Bio-X Research, 2021, Publish Ahead of Print, . | 0.2 | 0 |
| 775 | Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers, 2021, 13, 4343. | 3.7 | 8 |
| 776 | Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy. Journal of Inflammation Research, 2021, Volume 14, 3879-3890. | 3.5 | 21 |
| 777 | Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer, 2021, , . | 6.4 | 12 |
| 778 | Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 9044. | 4.1 | 7 |
| 779 | Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060. | 2.8 | 8 |
| 780 | Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepatic Oncology, 2022, 9, HEP41. | 4.2 | 2 |
| 781 | Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology, 2021, 22, 87. | 3.0 | 25 |
| 782 | PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs, 2022, 31, 415-423. | 4.1 | 78 |
| 783 | A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1129-1145. | 3.7 | 5 |
| 784 | Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. Frontiers in Immunology, 2021, 12, 720748. | 4.8 | 5 |
| 786 | Medical therapy of HCC. Journal of Hepatology, 2022, 76, 208-210. | 3.7 | 11 |
| 787 | Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. Oncologist, 2021, 26, e2227-e2238. | 3.7 | 23 |
| 788 | The effect of patient sex on the efficacy and safety of anticancer immunotherapy. Expert Opinion on Drug Safety, 2021, 20, 1535-1544. | 2.4 | 10 |
| 789 | Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma â€“ The Changing Tides. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1089-1115. | 3.7 | 28 |
| 790 | Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 1132-1143. | 2.0 | 2 |
| 791 | An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. Journal of Hepatology, 2021, , . | 3.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 792 | The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 2021, , 107815522110450. | 0.9 | 3 |
| 793 | Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882. | 3.7 | 15 |
| 794 | Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1195-1207. | 3.7 | 19 |
| 795 | Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunology, Immunotherapy, 2022, 71, 1063-1074. | 4.2 | 26 |
| 796 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311. | | 66 |
| 797 | Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1147-1158. | 3.7 | 8 |
| 798 | Heat Shock Protein Beta 1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 5483-5492. | 1.8 | 11 |
| 799 | Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Frontiers in Cell and Developmental Biology, 2021, 9, 730240. | 3.7 | 7 |
| 800 | Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. Medicine (United States), 2021, 100, e27013. | 1.0 | 4 |
| 801 | Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). Gastroenterology, 2021, 161, 879-898. | 1.3 | 123 |
| 802 | How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers, 2021, 13, 4719. | 3.7 | 7 |
| 803 | Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844. | 2.8 | 12 |
| 804 | Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103. | 3.6 | 10 |
| 805 | NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. Journal of Hepatology, 2022, 76, 446-457. | 3.7 | 121 |
| 806 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794. | | 43 |
| 807 | Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. OncoTargets and Therapy, 2021, Volume 14, 4859-4865. | 2.0 | 2 |
| 808 | Paradigm shift in the treatment options of hepatocellular carcinoma. Liver International, 2022, 42, 2067-2079. | 3.9 | 19 |
| 809 | Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell International, 2021, 21, 503. | 4.1 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 810 | Embracing cancer immunotherapy with vital micronutrients. World Journal of Clinical Oncology, 2021, 12, 712-724. | 2.3 | 10 |
| 811 | Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Digestive and Liver Disease, 2021, , . | 0.9 | 2 |
| 812 | Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets, 2021, 25, 645-658. | 3.4 | 5 |
| 813 | Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1700-1705. | 0.8 | 1 |
| 814 | Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052110445. | 1.0 | 2 |
| 815 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001. | 1.6 | 257 |
| 816 | Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Frontiers in Immunology, 2021, 12, 733530. | 4.8 | 23 |
| 817 | Systemic Therapy in Hepatocellular Carcinoma. , 0, , . | | 0 |
| 818 | Epigenetic mechanisms of liver tumor resistance to immunotherapy. World Journal of Hepatology, 2021, 13, 979-1002. | 2.0 | 5 |
| 819 | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 953-966. | 1.5 | 4 |
| 820 | The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology, 2021, 11, 635731. | 2.8 | 26 |
| 821 | HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines, 2021, 9, 1345. | 3.2 | 22 |
| 822 | Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology, 2021, 75, 960-974. | 3.7 | 217 |
| 823 | Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surgery and Nutrition, 2021, 10, 661-671. | 1.5 | 46 |
| 824 | The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. International Journal of General Medicine, 2021, Volume 14, 6343-6358. | 1.8 | 4 |
| 825 | Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. International Immunopharmacology, 2021, 100, 108128. | 3.8 | 13 |
| 826 | Controversies in the Management of Hepatitis B. Clinics in Liver Disease, 2021, 25, 785-803. | 2.1 | 4 |
| 827 | Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology, 2021, 100, 108135. | 3.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 828 | TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 611444. | 3.7 | 24 |
| 829 | Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Molecular Biosciences, 2020, 7, 609322. | 3.5 | 48 |
| 830 | The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Scientific Reports, 2021, 11, 2415. | 3.3 | 26 |
| 831 | Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. Journal of Comparative Effectiveness Research, 2021, 10, 343-352. | 1.4 | 13 |
| 832 | Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2021, 26, 39-52. | 2.4 | 9 |
| 833 | Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364. | | 0 |
| 834 | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics, 2021, 11, 3489-3501. | 10.0 | 35 |
| 835 | Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer, 2021, 10, 380-393. | 7.7 | 51 |
| 836 | Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer, 2021, 10, 137-150. | 7.7 | 21 |
| 837 | Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 2021, 19, 2775-2789. | 4.1 | 22 |
| 838 | Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers, 2021, 13, 192. | 3.7 | 27 |
| 839 | Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Research, 2021, 2021, . | 1.5 | 14 |
| 840 | Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma. , 2021, , 277-283. | | 0 |
| 841 | Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. Cancers, 2021, 13, 213. | 3.7 | 6 |
| 842 | The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals, 2021, 14, 43. | 3.8 | 8 |
| 843 | Checkpoint Inhibitors and Hepatotoxicity. Biomedicines, 2021, 9, 101. | 3.2 | 17 |
| 844 | Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean Journal of Radiology, 2021, 22, 1822-1833. | 3.4 | 9 |
| 845 | Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. SSRN Electronic Journal, 0, , . | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 846 | Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6. | 30.5 | 2,757 |
| 847 | Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer, 2021, 10, 451-460. | 7.7 | 5 |
| 848 | A Realâ€World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGETâ€HCC. Hepatology Communications, 2021, 5, 538-547. | 4.3 | 6 |
| 849 | Molecular-Targeted Therapies in Hepatocellular Carcinoma. Molecular and Translational Medicine, 2019, , 225-238. | 0.4 | 7 |
| 850 | Immune Therapies. Molecular and Translational Medicine, 2019, , 239-253. | 0.4 | 1 |
| 851 | Stromal and Immune Drivers of Hepatocarcinogenesis. Molecular and Translational Medicine, 2019, , 317-331. | 0.4 | 5 |
| 852 | Spatiotemporal Changes in Checkpoint Molecule Expression. Advances in Experimental Medicine and Biology, 2020, 1248, 167-200. | 1.6 | 5 |
| 853 | Immunotherapies in clinical development for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 351-363. | 4.1 | 28 |
| 854 | Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectrum, 2021, 5, pkaa100. | 2.9 | 12 |
| 855 | Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 74-81. | 1.3 | 36 |
| 856 | Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2021, 55, 263-270. | 2.2 | 3 |
| 857 | Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493. | 4.2 | 33 |
| 859 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235. | | 11 |
| 860 | Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720. | 7.7 | 427 |
| 861 | Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer, 2020, 9, 640-662. | 7.7 | 78 |
| 862 | Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. Journal of Clinical Investigation, 2020, 130, 4679-4693. | 8.2 | 42 |
| 863 | Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2020, 38, 1081. | 1.6 | 101 |
| 864 | Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research, 2020, 9, 620. | 1.6 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 865 | Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. World Journal of Clinical Cases, 2019, 7, 1253-1261. | 0.8 | 13 |
| 866 | Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8. | 1.4 | 41 |
| 867 | Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology, 2020, 8, 168-176. | 1.4 | 49 |
| 868 | Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. Journal of Liver Cancer, 2019, 19, 1-11. | 1.1 | 4 |
| 869 | Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma. Journal of Liver Cancer, 2020, 20, 128-134. | 1.1 | 6 |
| 870 | New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094. | 3.1 | 37 |
| 871 | Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. Aging, 2020, 12, 4970-4995. | 3.1 | 11 |
| 872 | Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. Aging, 2020, 12, 12187-12205. | 3.1 | 13 |
| 873 | Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging, 2020, 12, 25172-25188. | 3.1 | 5 |
| 874 | Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Research, 2020, 2020, . | 1.5 | 6 |
| 875 | Immune checkpoint inhibitor in liver cancerâ€"unique regional differences. Annals of Translational Medicine, 2020, 8, 1336-1336. | 1.7 | 4 |
| 876 | Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure. Annals of Translational Medicine, 2020, 8, 1700-1700. | 1.7 | 6 |
| 877 | Camrelizumabâ€"targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1614-1614. | 1.7 | 2 |
| 878 | Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. Current Medicinal Chemistry, 2020, 27, 4789-4805. | 2.4 | 6 |
| 879 | A Case of Acute Exacerbation of Hepatitis B by Pembrolizumab for a Lung Adenocarcinoma Patient with Hepatitis B Surface Antigen. Japanese Journal of Lung Cancer, 2020, 60, 115-119. | 0.1 | 2 |
| 880 | Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology, 2020, 26, 155-162. | 8.9 | 44 |
| 881 | Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers, 2020, 12, 1274. | 3.7 | 27 |
| 882 | Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303. | 3.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 883 | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers, 2021, 13, 90. | 3.7 | 21 |
| 884 | Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 232. | 4.1 | 6 |
| 885 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals, 2021, 14, 3. | 3.8 | 16 |
| 886 | Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals, 2021, 14, 28. | 3.8 | 17 |
| 887 | A Systematic Review and Network Meta-Analysis of Second-Line Therapy in Hepatocellular Carcinoma. Current Oncology, 2020, 27, 300-306. | 2.2 | 7 |
| 888 | Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. Current Oncology, 2020, 27, 173-180. | 2.2 | 5 |
| 889 | Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World Journal of Gastroenterology, 2019, 25, 3607-3618. | 3.3 | 14 |
| 890 | Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3704-3721. | 3.3 | 107 |
| 891 | Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 3870-3896. | 3.3 | 70 |
| 892 | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World Journal of Gastroenterology, 2020, 26, 1888-1900. | 3.3 | 20 |
| 893 | Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World Journal of Gastroenterology, 2020, 26, 3720-3736. | 3.3 | 32 |
| 894 | Targeting cancer stem cells in cholangiocarcinoma (Review). International Journal of Oncology, 2020, 57, 397-408. | 3.3 | 15 |
| 895 | Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review). Oncology Letters, 2020, 20, 45. | 1.8 | 12 |
| 896 | Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncology Reviews, 2020, 14, 515. | 1.8 | 5 |
| 897 | Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI). Journal of Cancer Research and Therapeutics, 2020, 16, 327-334. | 0.9 | 12 |
| 898 | Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. Immune Network, 2020, 20, e11. | 3.6 | 42 |
| 899 | Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2020, 12, 663-676. | 2.0 | 13 |
| 900 | Lenvatinib as first-line therapy for recurrentÂhepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation, 2020, 10, 297-306. | 1.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 901 | Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 669-675. | 4.9 | 29 |
| 902 | Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 302-310. | 4.9 | 214 |
| 903 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565. | 4.9 | 477 |
| 904 | Second-line treatment options in hepatocellular carcinoma. Drugs in Context, 2019, 8, 1-13. | 2.2 | 32 |
| 905 | The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine, 2021, 11, 4628-4634. | 0.0 | 0 |
| 906 | Infections virales chroniques (hÃ©patites, VIH) et impact sur le choix thÃ©rapeutique. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S272-2S279. | 0.0 | 0 |
| 907 | Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13, 1395-1405. | 2.0 | 35 |
| 908 | ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer Immunotherapy. Advanced Materials, 2021, 33, e2104037. | 21.0 | 89 |
| 909 | Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 694409. | 2.8 | 10 |
| 910 | Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World Journal of Gastrointestinal Oncology, 2021, 13, 1397-1411. | 2.0 | 9 |
| 911 | Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Seminars in Interventional Radiology, 2021, 38, 432-437. | 0.8 | 3 |
| 912 | Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers, 2021, 13, 5295. | 3.7 | 9 |
| 913 | Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2021, 13, 1136-1148. | 1.5 | 2 |
| 914 | The Immunology of Hepatocellular Carcinoma. Vaccines, 2021, 9, 1184. | 4.4 | 41 |
| 915 | Radioembolization in the Setting of Systemic Therapies. Seminars in Interventional Radiology, 2021, 38, 472-478. | 0.8 | 1 |
| 916 | Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Frontiers in Oncology, 2021, 11, 756672. | 2.8 | 12 |
| 917 | Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. Digestive Diseases, 2022, 40, 565-580. | 1.9 | 4 |
| 918 | Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety, 2021, , 1-10. | 2.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 919 | The ITA.LI.CA Consortium: how multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence.. Annals of Hepatology, 2021, , 100564. | 1.5 | 1 |
| 920 | Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. OncoTargets and Therapy, 2021, Volume 14, 5019-5026. | 2.0 | 4 |
| 921 | The management of post-transplantation recurrence of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 1-16. | 8.9 | 27 |
| 922 | Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFITY score. Journal of Hepatology, 2022, 76, 353-363. | 3.7 | 132 |
| 923 | Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharmaceutica Sinica B, 2021, 11, 3727-3739. | 12.0 | 34 |
| 924 | Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 9-21. | 7.7 | 29 |
| 925 | Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1233-1240. | 3.7 | 71 |
| 926 | Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer, 2021, 21, 1126. | 2.6 | 29 |
| 927 | Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , . | 1.3 | 3 |
| 928 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497. | 2.8 | 22 |
| 929 | Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Frontiers in Immunology, 2021, 12, 754961. | 4.8 | 16 |
| 930 | Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. Current Opinion in Oncology, 2022, 34, 95-106. | 2.4 | 9 |
| 931 | Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Scientific Reports, 2021, 11, 19711. | 3.3 | 9 |
| 932 | Î²-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Frontiers in Oncology, 2021, 11, 747282. | 2.8 | 11 |
| 933 | Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines, 2021, 9, 1524. | 3.2 | 10 |
| 934 | Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274. | 1.6 | 9 |
| 935 | Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. Seminars in Interventional Radiology, 2021, 38, 412-418. | 0.8 | 1 |
| 936 | Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278. | 12.2 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 937 | Integrated bioinformatics analyses of key genes involved in hepatocellular carcinoma immunosuppression. Oncology Letters, 2021, 22, 830. | 1.8 | 10 |
| 938 | The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo. Environmental Toxicology, 2022, 37, 92-100. | 4.0 | 6 |
| 939 | Updates in the Systemic Treatment of Hepatocellular Carcinoma. Oncology & Hematology Review, 2018, 14, 76. | 0.2 | 0 |
| 940 | Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. International Journal of Clinical Medicine, 2019, 10, 62-69. | 0.2 | 0 |
| 941 | Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-analysis, 2019, 7, 80-95. | 0.1 | 2 |
| 942 | Immunotherapy for hepatocellular cancer: beginning and future perspectives. Meditsinskiy Sovet, 2019, , 15-21. | 0.5 | 5 |
| 943 | The Management of Hepatocellular Carcinoma. , 2020, , 237-271. | | 1 |
| 944 | Second-line treatment of hepatocellular carcinoma: from theory to practical issues. Meditsinskiy Sovet, 2019, , 30-36. | 0.5 | 2 |
| 946 | Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. Journal of Immunotherapy and Precision Oncology, 2020, 3, 3-15. | 1.4 | 3 |
| 947 | Systemic therapy of hepatocellular carcinoma: reality and prospects. Annals of HPB Surgery, 2020, 25, 27-38. | 0.5 | 2 |
| 948 | Immunotherapy in hepatocellular carcinoma: Combination strategies. World Journal of Meta-analysis, 2020, 8, 190-209. | 0.1 | 1 |
| 949 | Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. Hepatobiliary Surgery and Nutrition, 2020, 9, 501-504. | 1.5 | 0 |
| 950 | Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1281-1295. | 3.7 | 10 |
| 952 | Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers, 2021, 13, 5448. | 3.7 | 5 |
| 953 | CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 759565. | 4.8 | 29 |
| 954 | Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics, 2021, 13, 1811. | 4.5 | 8 |
| 955 | Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers, 2021, 13, 5475. | 3.7 | 10 |
| 956 | Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, , . | 2.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 957 | Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873. | 3.2 | 19 |
| 958 | Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. Molecular Cancer Therapeutics, 2022, 21, 149-158. | 4.1 | 5 |
| 959 | Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. Journal of Hepatology, 2021, , . | 3.7 | 3 |
| 960 | Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. International Immunopharmacology, 2021, 101, 108322. | 3.8 | 18 |
| 962 | Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?. Annals of Translational Medicine, 2020, 8, 1701-1701. | 1.7 | 2 |
| 963 | Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. Case Reports in Oncological Medicine, 2020, 2020, 1-6. | 0.3 | 4 |
| 964 | Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159. | 0.4 | 0 |
| 965 | Pediatric hepatocellular carcinoma - the main differences from adult patients. Annals of HPB Surgery, 2020, 25, 85-94. | 0.5 | 0 |
| 966 | Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism, 2020, 21, 866-884. | 1.2 | 8 |
| 967 | Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. , 2020, 38, 89-91. | | 1 |
| 968 | Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241. | 1.6 | 8 |
| 969 | Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions. Healthbook TIMES Oncology Hematology, 2020, , . | 0.1 | 1 |
| 970 | Therapeutic Vaccines for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 113-158. | 0.2 | 1 |
| 972 | Hepatocellular Carcinoma: Western Experience. , 2020, , 81-118. | | 0 |
| 973 | Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48. | | 0 |
| 974 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A New Era in Treatment of Advanced Disease. Sohag Medical Journal (SMJ), 2020, 24, 20-26. | 0.1 | 0 |
| 975 | Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Frontiers in Oncology, 2021, 11, 747950. | 2.8 | 33 |
| 976 | Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell International, 2021, 21, 589. | 4.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 977 | Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81. | 2.5 | 6 |
| 978 | Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. Cancers, 2021, 13, 5586. | 3.7 | 13 |
| 979 | Clinical significance of herpes virus entry mediator expression in hepatitis B virusâ€‘related hepatocellular carcinoma. Oncology Letters, 2020, 20, 19. | 1.8 | 8 |
| 980 | Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer. World Chinese Journal of Digestology, 2020, 28, 605-616. | 0.1 | 0 |
| 981 | Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. Digestive Disease Interventions, 2020, 04, 373-381. | 0.2 | 0 |
| 982 | Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Current Gene Therapy, 2020, 20, 84-99. | 2.0 | 11 |
| 983 | Drugs in Development for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2018, 14, 542-544. | 0.1 | 1 |
| 984 | The Use of Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2019, 15, 48-50. | 0.1 | 1 |
| 985 | Current and Future Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2019, 15, 266-272. | 0.1 | 9 |
| 986 | Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. American Journal of Cancer Research, 2019, 9, 1536-1545. | 1.4 | 38 |
| 987 | Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. American Journal of Cancer Research, 2020, 10, 1085-1102. | 1.4 | 2 |
| 988 | Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1522-1533. | 1.4 | 4 |
| 989 | Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1658-1667. | 1.4 | 8 |
| 990 | Recent progress in treatment of hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 2993-3036. | 1.4 | 55 |
| 991 | Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 3157-3178. | 1.4 | 8 |
| 992 | Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532. | 1.7 | 0 |
| 993 | Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience. American Journal of Cancer Research, 2020, 10, 4547-4560. | 1.4 | 3 |
| 994 | Targeting the eicosanoid pathway in hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2456-2476. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 995 | Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 1745-1745. | 1.7 | 2 |
| 996 | Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database. Cancer Medicine, 2021, 10, 8754-8762. | 2.8 | 10 |
| 997 | The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198. | 3.7 | 35 |
| 998 | Long non-coding RNA HOMER3-AS1 drives hepatocellular carcinoma progression via modulating the behaviors of both tumor cells and macrophages. Cell Death and Disease, 2021, 12, 1103. | 6.3 | 14 |
| 999 | Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. Journal of Personalized Medicine, 2021, 11, 1199. | 2.5 | 4 |
| 1000 | Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 783236. | 4.8 | 66 |
| 1001 | Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 5665. | 3.7 | 5 |
| 1002 | Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investigation, 2021, 8, 22-22. | 3.0 | 1 |
| 1003 | Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy, 2021, , . | 2.0 | 0 |
| 1004 | Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195. | | 3 |
| 1005 | Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. International Journal of Molecular Sciences, 2021, 22, 12947. | 4.1 | 4 |
| 1006 | Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. International Immunopharmacology, 2021, 101, 108340. | 3.8 | 23 |
| 1007 | Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Oncology, 2021, 11, 751159. | 2.8 | 16 |
| 1008 | Immunotherapies for hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2022, 19, 151-172. | 27.6 | 643 |
| 1009 | Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology, 2022, 75, 1257-1274. | 7.3 | 26 |
| 1010 | Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers, 2021, 13, 5797. | 3.7 | 13 |
| 1011 | Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. International Immunopharmacology, 2021, 101, 108337. | 3.8 | 3 |
| 1012 | Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma. Experimental Cell Research, 2021, 409, 112910. | 2.6 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1013 | Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330. | 4.5 | 25 |
| 1014 | Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 361-369. | 4.1 | 68 |
| 1016 | Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2021, 20, 153303382110638. | 1.9 | 10 |
| 1017 | Progress in the Treatment of Hepatocellular Carcinoma Complicated with Portal Vein Tumor Thrombus. Advances in Clinical Medicine, 2021, 11, 6018-6023. | 0.0 | 0 |
| 1018 | Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. Journal of Cancer Research and Practice, 2021, 8, 127. | 0.2 | 2 |
| 1019 | Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 259-272. | 1.6 | 3 |
| 1020 | HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. American Journal of Clinical Pathology, 2022, 158, 62-69. | 0.7 | 4 |
| 1021 | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1022 | Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1243-1255. | 0.8 | 67 |
| 1023 | Immunotherapy in older patients with hepatocellular carcinoma. European Journal of Cancer, 2022, 162, 76-98. | 2.8 | 8 |
| 1024 | Organoids as research models for hepatocellular carcinoma. Experimental Cell Research, 2022, 411, 112987. | 2.6 | 7 |
| 1025 | Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. European Journal of Gastroenterology and Hepatology, 2022, 34, 213-219. | 1.6 | 10 |
| 1026 | Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532-1532. | 1.7 | 2 |
| 1027 | Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296. | | 0 |
| 1028 | Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. BMC Cancer, 2021, 21, 1347. | 2.6 | 3 |
| 1029 | Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology, 2022, 27, 100677. | 1.5 | 5 |
| 1030 | Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 401-413. | 4.1 | 9 |
| 1031 | Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Bioscience Reports, 2022, 42, . | 2.4 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1032 | Clinical pharmacology: Current innovations and future challenges. Fundamental and Clinical Pharmacology, 2022, 36, 456-467. | 1.9 | 2 |
| 1033 | Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621. | 3.7 | 34 |
| 1034 | A Preliminary Study on Fructus Aurantii Extract Against Hepatocarcinoma via Glycolysis and PD-1/PD-L1 Pathway. Pharmacological Research Modern Chinese Medicine, 2022, 2, 100051. | 1.2 | 0 |
| 1035 | EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 780509. | 4.8 | 2 |
| 1036 | Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology, 2022, 18, 1423-1435. | 2.4 | 14 |
| 1037 | Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 208-218. | 8.1 | 105 |
| 1038 | Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. , 2022, 10, e003133. | | 20 |
| 1039 | Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology, 2022, 86, 799-815. | 9.6 | 28 |
| 1040 | Corticosteroids for highâ€grade immune checkpoint inhibitorâ€“mediated hepatitis: Is less more?. Hepatology, 2022, 75, 508-510. | 7.3 | 1 |
| 1041 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1. | 8.2 | 68 |
| 1042 | Hepatic Tumor Stiffness Measured by Shear Wave Elastography is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1043 | Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3. | 6.8 | 94 |
| 1044 | Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Frontiers in Immunology, 2022, 13, 815575. | 4.8 | 63 |
| 1045 | Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences, 2021, 8, 800679. | 3.5 | 2 |
| 1046 | Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229. | 8.1 | 79 |
| 1047 | Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 657512. | 2.8 | 16 |
| 1048 | Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. Frontiers in Pharmacology, 2021, 12, 786174. | 3.5 | 8 |
| 1049 | Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. Frontiers in Immunology, 2022, 13, 781660. | 4.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1050 | A hepatocellularis carcinoma komplex kezelÃ©se.. Orvosi Hetilap, 2022, 162, 2-31. | 0.4 | 1 |
| 1051 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90. | 10.7 | 526 |
| 1052 | Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology, 2022, 76, 630-645. | 7.3 | 13 |
| 1053 | The new insight of treatment in Cholangiocarcinoma. Journal of Cancer, 2022, 13, 450-464. | 2.5 | 18 |
| 1054 | Targets of immunotherapy for hepatocellular carcinoma: An update. World Journal of Hepatology, 2022, 14, 140-157. | 2.0 | 7 |
| 1055 | Potential therapeutic strategies to combat HCC. Current Molecular Pharmacology, 2022, 15, . | 1.5 | 1 |
| 1056 | The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma. Laboratory Investigation, 2022, 102, 613-620. | 3.7 | 2 |
| 1058 | A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Frontiers in Pharmacology, 2021, 12, 820446. | 3.5 | 6 |
| 1059 | Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149. | 2.5 | 14 |
| 1060 | Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization. International Journal of Pharmaceutics, 2022, 616, 121466. | 5.2 | 9 |
| 1061 | The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors. Nutrition and Cancer, 2022, 74, 2815-2828. | 2.0 | 4 |
| 1062 | Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. Future Oncology, 2022, , . | 2.4 | 4 |
| 1063 | Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research, 2022, 412, 113042. | 2.6 | 4 |
| 1064 | Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists. Diagnostics, 2022, 12, 395. | 2.6 | 2 |
| 1065 | T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 203-214. | 4.9 | 1 |
| 1066 | C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Frontiers in Immunology, 2022, 13, 808101. | 4.8 | 19 |
| 1067 | Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell International, 2022, 22, 73. | 4.1 | 21 |
| 1068 | Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460. | 0.9 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1069 | Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma. Aging, 2022, 14, 1473-1491. | 3.1 | 10 |
| 1070 | Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 2022, 11, 571-591. | 2.8 | 29 |
| 1071 | Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 337-346. | 4.1 | 6 |
| 1072 | The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Frontiers in Oncology, 2021, 11, 801379. | 2.8 | 21 |
| 1073 | New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. International Journal of Biological Sciences, 2022, 18, 2775-2794. | 6.4 | 27 |
| 1074 | Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective. , 2022, , 177-183. | | 0 |
| 1075 | Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. Advances in Cancer Research, 2022, , 367-413. | 5.0 | 6 |
| 1076 | Implications of genetic heterogeneity in hepatocellular cancer. Advances in Cancer Research, 2022, , 103-135. | 5.0 | 5 |
| 1077 | A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2022, 21, 153303382210751. | 1.9 | 21 |
| 1078 | Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma. Advances in Clinical Medicine, 2022, 12, 1724-1729. | 0.0 | 0 |
| 1079 | A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response. Mathematical Biosciences and Engineering, 2022, 19, 4719-4736. | 1.9 | 1 |
| 1080 | Neurological complications of GI cancers. , 2022, , 365-386. | | 0 |
| 1081 | Long-term remission by nivolumab monotherapy for sorafenib-refractory hepatocellular carcinoma. Journal of Cancer Research and Practice, 2022, 9, 41. | 0.2 | 1 |
| 1082 | Role of transcription factors in hepatocellular carcinoma. , 2022, , 149-163. | | 0 |
| 1083 | Down-regulation of TRPV6 Is Associated With Adverse Prognosis in Hepatocellular Carcinoma Treated With Curative Resection. Cancer Genomics and Proteomics, 2022, 19, 259-269. | 2.0 | 1 |
| 1084 | PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. Future Oncology, 2022, 18, 1691-1703. | 2.4 | 4 |
| 1085 | A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000. | 1.4 | 0 |
| 1086 | Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 824208. | 2.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1087 | Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 842220. | 3.7 | 8 |
| 1088 | Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978. | | 16 |
| 1089 | Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 810269. | 2.8 | 14 |
| 1090 | Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. Cancer Cell International, 2022, 22, 97. | 4.1 | 7 |
| 1091 | Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. Annals of HPB Surgery, 2022, 27, 33-39. | 0.5 | 0 |
| 1092 | The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 425-435. | 4.1 | 3 |
| 1093 | Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. Seminars in Cancer Biology, 2022, 86, 1175-1185. | 9.6 | 2 |
| 1094 | Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunology, Immunotherapy, 2022, 71, 2371-2379. | 4.2 | 4 |
| 1095 | Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research, 2022, 28, 3499-3508. | 7.0 | 32 |
| 1096 | Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 157-170. | 3.7 | 23 |
| 1097 | OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunology, Immunotherapy, 2022, 71, 2677-2689. | 4.2 | 7 |
| 1098 | Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 233-263. | 3.7 | 27 |
| 1099 | Lenvatinib plus pembrolizumab for systemic therapy-naÃ¯ve and -experienced unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 2631-2643. | 4.2 | 23 |
| 1100 | Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Annals of Medicine, 2022, 54, 803-811. | 3.8 | 9 |
| 1102 | Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 814120. | 2.8 | 3 |
| 1103 | Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers, 2022, 14, 1760. | 3.7 | 20 |
| 1104 | Trajectory of immune evasion and cancer progression in hepatocellular carcinoma. Nature Communications, 2022, 13, 1441. | 12.8 | 28 |
| 1105 | Immunotherapy and Transarterial therapy of <scp>HCC</scp>: What the interventional radiologist needs to know about the changing landscape of <scp>HCC</scp> treatment?. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 478-482. | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1106 | Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Frontiers in Oncology, 2022, 12, 764923. | 2.8 | 4 |
| 1107 | Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver Cancer, 2022, 11, 315-328. | 7.7 | 31 |
| 1108 | Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediateâ€Stage Hepatocellular Carcinoma, What Else Can We Do?. Frontiers in Oncology, 2022, 12, 824799. | 2.8 | 3 |
| 1109 | ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Genetics, 2022, 13, 842351. | 2.3 | 8 |
| 1110 | Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2022, 22, 253-264. | 3.1 | 20 |
| 1111 | Immune-related lincRNA pairs predict prognosis and therapeutic response in hepatocellular carcinoma. Scientific Reports, 2022, 12, 4259. | 3.3 | 1 |
| 1112 | SIRPÎ± and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. Journal of Translational Medicine, 2022, 20, 140. | 4.4 | 21 |
| 1113 | Comparative safety, efficacy and survival outcome of anti-PD-1 immunotherapy in colorectal cancer patients with vs without hepatitis B virus infection: a multicenter cohort study. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, . | 2.5 | 6 |
| 1114 | Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers, 2022, 14, 1526. | 3.7 | 7 |
| 1115 | Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2022, 31, 483-494. | 4.1 | 2 |
| 1116 | Prognostic significance of <scp>albuminâ€“bilirubin</scp> score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 662-670. | 1.8 | 5 |
| 1117 | Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. Frontiers in Oncology, 2022, 12, 821903. | 2.8 | 2 |
| 1118 | Phase IIÂclinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncology, 2022, 18, 2173-2191. | 2.4 | 1 |
| 1119 | Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 2022, 14, 1747. | 3.7 | 36 |
| 1120 | The Treatment Landscape of Advanced Hepatocellular Carcinoma. Current Oncology Reports, 2022, 24, 917-927. | 4.0 | 21 |
| 1121 | LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 203-220. | 3.7 | 8 |
| 1122 | Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2449-2460. | 7.0 | 39 |
| 1123 | Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Frontiers in Oncology, 2022, 12, 807102. | 2.8 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1124 | Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 2022, 20, 1752-1763. | 4.1 | 3 |
| 1125 | Immune checkpoint inhibitors for hepatocellular carcinoma â€“ A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383. | 1.7 | 3 |
| 1126 | Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Experimental Hematology and Oncology, 2022, 11, 20. | 5.0 | 6 |
| 1127 | Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl) Tj ETQq1 1 0.784314 rgBT /Ove | 4.8 | 3 |
| 1128 | Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626. | 7.3 | 97 |
| 1129 | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12. | 2.8 | 43 |
| 1130 | Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology, 2022, 42, 101748. | 1.6 | 2 |
| 1131 | Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence. Engineering, 2022, 10, 57-64. | 6.7 | 4 |
| 1132 | Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355. | 2.4 | 8 |
| 1133 | Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology, 2021, 12, 794099. | 4.8 | 34 |
| 1134 | What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168. | 4.8 | 18 |
| 1135 | Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdominal Radiology, 2022, 47, 969-980. | 2.1 | 11 |
| 1136 | Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology, 2021, 11, 798832. | 2.8 | 16 |
| 1137 | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133. | 2.8 | 83 |
| 1138 | Response Evaluation and Survival Prediction Following PDâ€1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. Frontiers in Oncology, 2021, 11, 764189. | 2.8 | 12 |
| 1139 | Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 6307. | 3.7 | 17 |
| 1140 | Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers, 2021, 13, 6337. | 3.7 | 3 |
| 1141 | A targetable LIFRâ^'NF-Î¹Bâ^'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333. | 12.8 | 117 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1142 | Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2136128. | 5.9 | 29 |
| 1143 | Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences, 2021, 8, 781307. | 3.5 | 10 |
| 1144 | Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies. Medicine (United States), 2021, 100, e28113. | 1.0 | 5 |
| 1145 | Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center. Journal of Gastrointestinal Oncology, 2021, 12, 2943-2951. | 1.4 | 3 |
| 1146 | Ðembrolizumab as second line therapy for hepatocellular patient. Meditsinskiy Sovet, 2021, , 150-154. | 0.5 | 0 |
| 1147 | Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Frontiers in Immunology, 2021, 12, 792781. | 4.8 | 39 |
| 1148 | A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China. Frontiers in Oncology, 2021, 11, 788635. | 2.8 | 9 |
| 1149 | Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis. Medicine (United States), 2021, 100, e27987. | 1.0 | 3 |
| 1150 | Stable liver graft post antiâ€PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. Pediatric Transplantation, 2022, 26, e14209. | 1.0 | 11 |
| 1151 | Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 2038-2049. | 2.0 | 3 |
| 1152 | Comprehensive analysis of spatial architecture in primary liver cancer. Science Advances, 2021, 7, eabg3750. | 10.3 | 113 |
| 1153 | Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490. | 3.1 | 0 |
| 1154 | The Evolving Systemic Treatment for Advanced Hepatocellular Carcinoma. Healthbook TIMES Oncology Hematology, 2021, , . | 0.1 | 1 |
| 1155 | Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. Cancer Medicine, 2022, 11, 602-617. | 2.8 | 1 |
| 1156 | Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210861. | 3.2 | 13 |
| 1157 | Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review. BioScience Trends, 2022, 16, 130-141. | 3.4 | 14 |
| 1158 | Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncology, 2022, 18, 2269-2288. | 2.4 | 12 |
| 1159 | Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology, 2022, 76, 1649-1659. | 7.3 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1160 | Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566. | 7.0 | 31 |
| 1161 | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical Cancer Research, 2022, 28, 2547-2554. | 7.0 | 32 |
| 1162 | Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers, 2022, 14, 2056. | 3.7 | 24 |
| 1163 | Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 333-339. | 3.0 | 65 |
| 1164 | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 315-325. | 3.7 | 5 |
| 1165 | Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers. Frontiers in Immunology, 2022, 13, 810539. | 4.8 | 4 |
| 1166 | Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry, 2022, 237, 114376. | 5.5 | 3 |
| 1167 | Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018. | 3.7 | 15 |
| 1168 | Systemic Therapy in Metastatic Hepatocellular Carcinoma. Current Gastroenterology Reports, 2022, 24, 65-71. | 2.5 | 4 |
| 1169 | Efficacy and safety of <scp>PD</scp>â€1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Medicine, 2022, 11, 3612-3622. | 2.8 | 13 |
| 1170 | Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Frontiers in Oncology, 2022, 12, 874473. | 2.8 | 22 |
| 1187 | Updates on clinical trials for the management of hepatocellular carcinoma. , 2022, , 259-273. | | 0 |
| 1188 | Recent advances in medical treatment of hepatocellular cancer. , 2022, , 365-375. | | 0 |
| 1189 | Immunotherapy for hepatocellular cancer: a review of current status. , 2022, , 245-258. | | 0 |
| 1190 | Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer. Advances in Clinical Medicine, 2022, 12, 3360-3366. | 0.0 | 0 |
| 1191 | Immune checkpoint inhibitors for hepatocellular carcinoma. , 2022, , 215-223. | | 0 |
| 1192 | Therapeutic options for the management of hepatocellular carcinoma. , 2022, , 43-62. | | 0 |
| 1193 | Precision medicine approaches for treating hepatocellular carcinoma. , 2022, , 287-299. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1194 | Resistance of Lenvatinib in hepatocellular carcinoma. Current Cancer Drug Targets, 2022, 22, . | 1.6 | 5 |
| 1195 | Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma. Frontiers in Genetics, 2022, 13, 818403. | 2.3 | 3 |
| 1196 | Tumour burden score and immuneâ€related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , . | 1.3 | 0 |
| 1197 | Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. Cancer Immunology Research, 2022, 10, 728-744. | 3.4 | 27 |
| 1198 | Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Investigational New Drugs, 2022, 40, 789-797. | 2.6 | 14 |
| 1199 | Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers, 2022, 14, 2357. | 3.7 | 18 |
| 1200 | Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 533-546. | 2.2 | 6 |
| 1201 | Prediction of Drug-Drug Interaction Using an Attention-Based Graph Neural Network on Drug Molecular Graphs. Molecules, 2022, 27, 3004. | 3.8 | 13 |
| 1202 | Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Frontiers in Oncology, 2022, 12, . | 2.8 | 1 |
| 1203 | Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401. | 13.2 | 126 |
| 1204 | Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications, 2022, 6, 1776-1785. | 4.3 | 7 |
| 1206 | Immune cell infiltration and immunotherapy in hepatocellular carcinoma. Mathematical Biosciences and Engineering, 2022, 19, 7178-7200. | 1.9 | 2 |
| 1207 | Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 50-57. | 0.7 | 1 |
| 1208 | Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1197-1206. | 2.8 | 13 |
| 1209 | Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Frontiers in Pharmacology, 2022, 13, . | 3.5 | 4 |
| 1210 | Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Expert Opinion on Investigational Drugs, 2022, 31, 693-706. | 4.1 | 2 |
| 1211 | Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. American Journal of Cancer Research, 2022, 12, 1606-1620. | 1.4 | 0 |
| 1212 | Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/Î²â€catenin signal activation. Oncology Letters, 2022, 24, . | 1.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1218 | Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127. | 2.8 | 20 |
| 1219 | An exploratory clinical trial of apatinib combined with intensityâ€modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Medicine, 0, , . | 2.8 | 5 |
| 1220 | Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Frontiers in Immunology, 0, 13, . | 4.8 | 7 |
| 1221 | Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 263-274. | 1.1 | 1 |
| 1222 | Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Frontiers in Oncology, 0, 12, . | 2.8 | 22 |
| 1223 | Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 0, 10, . | 3.7 | 1 |
| 1224 | Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. International Journal of Clinical Oncology, 0, , . | 2.2 | 2 |
| 1225 | Hepatocellular Carcinoma: Pick the Winnerâ€"Tyrosine Kinase Inhibitor Versus Immuno-oncology Agentâ€"Based Combinations. Journal of Clinical Oncology, 2022, 40, 2763-2773. | 1.6 | 18 |
| 1226 | Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean Journal of Transplantation, 2022, 36, 82-98. | 0.1 | 9 |
| 1227 | Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 141-149. | 2.4 | 4 |
| 1228 | First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, 10, 1304. | 3.2 | 9 |
| 1229 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, . | 8.6 | 17 |
| 1230 | Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. Advanced Science, 2022, 9, . | 11.2 | 17 |
| 1231 | Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review. Translational Cancer Research, 2021, . | 1.0 | 1 |
| 1232 | Interventional oncology update. European Journal of Radiology Open, 2022, 9, 100430. | 1.6 | 2 |
| 1233 | Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. Liver Cancer, 2022, 11, 426-439. | 7.7 | 11 |
| 1234 | The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology and Medicine, 2022, 19, 1-16. | 3.0 | 18 |
| 1235 | Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205. | | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1236 | Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatology International, 2022, 16, 1150-1160. | 4.2 | 35 |
| 1237 | Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology, 2023, 77, 6-9. | 7.3 | 1 |
| 1238 | Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2023, 478, 23-37. | 3.1 | 7 |
| 1239 | Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. World Journal of Gastrointestinal Oncology, 2022, 14, 1103-1114. | 2.0 | 8 |
| 1241 | Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540. | 46.4 | 134 |
| 1242 | Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Frontiers in Immunology, 0, 13, . | 4.8 | 2 |
| 1243 | Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, . | 2.8 | 19 |
| 1244 | Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma. BioMed Research International, 2022, 2022, 1-24. | 1.9 | 2 |
| 1245 | Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Meditsinskiy Sovet, 2022, , 157-162. | 0.5 | 0 |
| 1247 | The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-Î²B Signaling. Medicina (Lithuania), 2022, 58, 798. | 2.0 | 3 |
| 1248 | Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. World Journal of Hepatology, 2022, 14, 1074-1086. | 2.0 | 1 |
| 1249 | Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis. Pathology and Oncology Research, 0, 28, . | 1.9 | 6 |
| 1250 | Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World Journal of Clinical Oncology, 2022, 13, 448-472. | 2.3 | 6 |
| 1251 | MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers, 2022, 14, 2880. | 3.7 | 7 |
| 1252 | Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, . | 4.8 | 18 |
| 1253 | The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132. | 3.2 | 10 |
| 1254 | ICIs-Related Cardiotoxicity in Different Types of Cancer. Journal of Cardiovascular Development and Disease, 2022, 9, 203. | 1.6 | 11 |
| 1255 | Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with antiâ€VEGF/TKI and immunotherapy. Hepatology, 2022, 76, 1203-1218. | 7.3 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1256 | Emerging insights on immunotherapy in liver cancer. Antioxidants and Redox Signaling, 0, , . | 5.4 | 4 |
| 1257 | Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. Frontiers in Immunology, 0, 13, . | 4.8 | 16 |
| 1258 | Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 3.5 | 12 |
| 1259 | Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 969-978. | 2.5 | 9 |
| 1260 | The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , . | 0.2 | 0 |
| 1261 | Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 3.5 | 6 |
| 1262 | Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 571-581. | 3.7 | 10 |
| 1263 | Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. Cancers, 2022, 14, 3213. | 3.7 | 10 |
| 1264 | Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Frontiers in Oncology, 0, 12, . | 2.8 | 2 |
| 1265 | The focus clinical research in intrahepatic cholangiocarcinoma. European Journal of Medical Research, 2022, 27, . | 2.2 | 7 |
| 1266 | Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer, 2022, 11, 558-571. | 7.7 | 6 |
| 1267 | Cold Atmospheric Plasma Conveys Selectivity Against Hepatocellular Carcinoma Cells via Triggering EGFR(Tyr1068)-Mediated Autophagy. Frontiers in Oncology, 0, 12, . | 2.8 | 4 |
| 1268 | Necroptosis-Related Genes Signatures Identified Molecular Subtypes and Underlying Mechanisms in Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 1 |
| 1269 | Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. Molecular Therapy - Oncolytics, 2022, 26, 226-244. | 4.4 | 4 |
| 1270 | Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 0 |
| 1271 | Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Frontiers in Oncology, 0, 12, . | 2.8 | 10 |
| 1272 | Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs. Clinical Cancer Research, 2022, 28, 3405-3407. | 7.0 | 2 |
| 1273 | Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology and Hepatology, 2022, 7, 1049-1060. | 8.1 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1274 | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infectious Diseases, 2022, 22, . | 2.9 | 4 |
| 1275 | Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers, 2022, 14, 3373. | 3.7 | 17 |
| 1276 | Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Annals of Hepatology, 2022, 27, 100740. | 1.5 | 1 |
| 1277 | Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. Cancer Gene Therapy, 2022, 29, 1951-1960. | 4.6 | 17 |
| 1278 | Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). Liver Cancer, 2022, 11, 511-526. | 7.7 | 11 |
| 1279 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. European Radiology, 2023, 33, 512-522. | 4.5 | 15 |
| 1280 | Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132. | 3.2 | 8 |
| 1281 | Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. Middle East Journal of Digestive Diseases, 2022, 14, 244-253. | 0.4 | 1 |
| 1282 | Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma. Immunogenetics, 0, , . | 2.4 | 1 |
| 1283 | Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Cytokine and Growth Factor Reviews, 2022, 67, 1-10. | 7.2 | 4 |
| 1284 | A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma. Cells, 2022, 11, 2302. | 4.1 | 4 |
| 1285 | Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World Journal of Gastroenterology, 2022, 28, 3573-3585. | 3.3 | 4 |
| 1286 | Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 371-384. | 4.2 | 7 |
| 1287 | Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?. Asia-Pacific Journal of Clinical Oncology, 0, , . | 1.1 | 0 |
| 1288 | Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. BMJ Case Reports, 2022, 15, e250009. | 0.5 | 1 |
| 1289 | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 4.8 | 14 |
| 1290 | The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. Journal of Clinical Medicine, 2022, 11, 4874. | 2.4 | 5 |
| 1292 | DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1293 | Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. Cancers, 2022, 14, 3892. | 3.7 | 1 |
| 1294 | Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. Liver Cancer, 2023, 12, 44-56. | 7.7 | 1 |
| 1295 | Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-27. | 2.2 | 1 |
| 1297 | Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 413-419. | 1.3 | 12 |
| 1298 | Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 2.3 | 2 |
| 1299 | A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell International, 2022, 22, . | 4.1 | 3 |
| 1300 | Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. Clinical and Experimental Medicine, 2023, 23, 579-590. | 3.6 | 6 |
| 1301 | Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology, 0, 12, . | 2.8 | 4 |
| 1302 | Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. Frontiers in Oncology, 0, 12, . | 2.8 | 4 |
| 1303 | Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Scientific Reports, 2022, 12, . | 3.3 | 6 |
| 1304 | Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Medicinal Chemistry, 0, , . | 2.3 | 1 |
| 1305 | Interventional radiology meets immuno-oncology for hepatocellular carcinoma. Journal of Hepatology, 2022, , . | 3.7 | 5 |
| 1306 | Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. Journal of Hepatocellular Carcinoma, 0, Volume 9, 855-867. | 3.7 | 5 |
| 1307 | Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Frontiers in Immunology, 0, 13, . | 4.8 | 6 |
| 1308 | Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. Hepatology International, 2022, 16, 1179-1187. | 4.2 | 6 |
| 1309 | Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection, 2022, , . | 0.8 | 1 |
| 1310 | Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 420-429. | 1.3 | 9 |
| 1311 | Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer, 2022, 22, . | 2.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1312 | The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology, 2023, 77, 1773-1796. | 7.3 | 101 |
| 1313 | A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 3.5 | 3 |
| 1314 | Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Current Oncology, 2022, 29, 5489-5507. | 2.2 | 19 |
| 1315 | Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model. Scientific Reports, 2022, 12, . | 3.3 | 10 |
| 1316 | Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer, 2022, 174, 68-77. | 2.8 | 45 |
| 1317 | Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Frontiers in Oncology, 0, 12, . | 2.8 | 13 |
| 1318 | Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences, 2022, 23, 10038. | 4.1 | 4 |
| 1319 | Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Frontiers in Oncology, 0, 12, . | 2.8 | 7 |
| 1320 | Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1011-1027. | 3.7 | 3 |
| 1321 | Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology, 2023, 164, 72-88.e18. | 1.3 | 48 |
| 1322 | Immune checkpoint inhibitor therapy for hepatocellular carcinoma. Annals of Gastroenterology, 2022, , . | 0.6 | 0 |
| 1323 | Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 1324 | Available Immunotherapy Drugs in Oncology. Current Clinical Pathology, 2022, , 5-23. | 0.0 | 0 |
| 1325 | Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. Cancer Control, 2022, 29, 107327482211112. | 1.8 | 17 |
| 1326 | Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities. Hepatoma Research, 0, 8, 32. | 1.5 | 0 |
| 1327 | Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma. Journal of Cancer, 2022, 13, 3199-3208. | 2.5 | 4 |
| 1328 | Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776. | | 0 |
| 1329 | Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer, 2023, 12, 116-128. | 7.7 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1330 | Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers, 2022, 14, 4201. | 3.7 | 1 |
| 1331 | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Frontiers in Oncology, 0, 12, . | 2.8 | 2 |
| 1333 | Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Frontiers in Genetics, 0, 13, . | 2.3 | 4 |
| 1334 | Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology, 2022, 13, . | 2.1 | 6 |
| 1335 | Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology, 0, 12, . | 2.8 | 9 |
| 1336 | Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surgical Oncology, 2022, 44, 101844. | 1.6 | 7 |
| 1337 | A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma. , 2022, 1, 187-193. | | 1 |
| 1338 | The immune landscape of hepatocellular carcinomaâ€‘where we are? (Review). Oncology Letters, 2022, 24, . | 1.8 | 6 |
| 1340 | Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128. | | 4 |
| 1341 | A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462. | 2.2 | 6 |
| 1342 | Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open, 2022, 6, . | 1.7 | 20 |
| 1343 | Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 4929-4942. | 3.3 | 5 |
| 1344 | Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Frontiers in Oncology, 0, 12, . | 2.8 | 6 |
| 1345 | Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. Frontiers in Oncology, 0, 12, . | 2.8 | 2 |
| 1346 | PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. Biomolecules, 2022, 12, 1226. | 4.0 | 4 |
| 1347 | Immunotherapy and Hepatocellular Cancer: Where Are We Now?. Cancers, 2022, 14, 4523. | 3.7 | 7 |
| 1348 | The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology, 0, 13, . | 4.8 | 83 |
| 1349 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, . | 2.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1350 | Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2023, 115, 202-213. | 0.8 | 25 |
| 1351 | Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers, 2022, 14, 4631. | 3.7 | 12 |
| 1353 | Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, . | 1.9 | 1 |
| 1354 | Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 4.8 | 11 |
| 1355 | Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 4616. | 3.7 | 18 |
| 1356 | Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 11363. | 4.1 | 6 |
| 1357 | Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World Journal of Gastrointestinal Oncology, 2022, 14, 1622-1636. | 2.0 | 6 |
| 1358 | Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. Frontiers in Genetics, 0, 13, . | 2.3 | 1 |
| 1359 | Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice. OncoTargets and Therapy, 0, Volume 15, 1079-1094. | 2.0 | 4 |
| 1360 | SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncology, 0, , . | 2.4 | 3 |
| 1361 | Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Global Oncology, 2022, , . | 1.8 | 4 |
| 1362 | Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, . | 2.3 | 4 |
| 1363 | Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety. Liver Cancer, 2023, 12, 145-155. | 7.7 | 2 |
| 1364 | Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomaterials Science and Engineering, 2022, 8, 4819-4826. | 5.2 | 2 |
| 1365 | Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer, 2023, 12, 72-84. | 7.7 | 16 |
| 1366 | Research Progress of Systematic Therapy for Advanced Primary Liver Cancer. Advances in Clinical Medicine, 2022, 12, 9622-9627. | 0.0 | 0 |
| 1367 | Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression. Technology in Cancer Research and Treatment, 2022, 21, 153303382211313. | 1.9 | 6 |
| 1368 | Research Advancements in Hepatocellular Carcinoma and Ferroptosis. Advances in Clinical Medicine, 2022, 12, 9363-9368. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1369 | Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211336. | 1.9 | 4 |
| 1370 | Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma. Annals of Cancer Research and Therapy, 2022, 30, 121-124. | 0.3 | 1 |
| 1371 | First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Current Oncology, 2022, 29, 7305-7326. | 2.2 | 2 |
| 1372 | Hepatocellular Carcinoma Medical Therapy. Updates in Surgery Series, 2023, , 173-179. | 0.1 | 0 |
| 1373 | Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World Journal of Hepatology, 0, 14, 1862-1874. | 2.0 | 5 |
| 1374 | Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125. | 3.7 | 11 |
| 1375 | Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics, 2022, 14, 2263. | 4.5 | 3 |
| 1376 | Immunotherapy and Hepatocellular Carcinoma. , 0, , . | | 0 |
| 1377 | Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |
| 1378 | Single-cell transcriptomics reveals the role of Macrophage-NaÃ¯ve CD4â€‰+â€‰T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. Journal of Translational Medicine, 2022, 20, . | 4.4 | 9 |
| 1379 | Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 14809-14831. | 6.4 | 5 |
| 1380 | Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy, 2022, 14, 1341-1351. | 2.0 | 9 |
| 1381 | Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. Cancers, 2022, 14, 4896. | 3.7 | 4 |
| 1382 | Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. Clinical Radiology, 2023, 78, e37-e44. | 1.1 | 1 |
| 1383 | Sex Differences in Genomic Features of Hepatitis Bâ€“Associated Hepatocellular Carcinoma With Distinct Antitumor Immunity. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 327-354. | 4.5 | 5 |
| 1384 | 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705. | 8.9 | 102 |
| 1385 | Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. Cancers, 2022, 14, 5013. | 3.7 | 12 |
| 1387 | bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and antiâ€angiogenic agent apatinib combination therapy. Clinical and Translational Medicine, 2022, 12, . | 4.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1388 | Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy. ACS Nano, 2022, 16, 18921-18935. | 14.6 | 3 |
| 1389 | An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 10 |
| 1390 | Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Proliferation, 2023, 56, . | 5.3 | 16 |
| 1391 | Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer, 2022, 22, . | 2.6 | 3 |
| 1392 | Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. Frontiers in Immunology, 0, 13, . | 4.8 | 13 |
| 1393 | Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers, 2022, 14, 5173. | 3.7 | 6 |
| 1396 | Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414. | | 18 |
| 1397 | Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1149-1169. | 3.7 | 3 |
| 1398 | An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2023, 32, 101-117. | 1.5 | 4 |
| 1400 | Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022. | 2.5 | 4 |
| 1401 | A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research, 2023, 281, 289-298. | 1.6 | 3 |
| 1402 | Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211348. | 1.3 | 2 |
| 1403 | Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences, 2022, 23, 13961. | 4.1 | 10 |
| 1404 | Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 203-222. | 17.8 | 113 |
| 1405 | Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World Journal of Transplantation, 0, 12, 331-346. | 1.6 | 2 |
| 1406 | Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Frontiers in Immunology, 0, 13, . | 4.8 | 9 |
| 1407 | Have We Found the â€œHoly Grailâ€•That May Predict Response to Immunotherapy in Hepatocellular Carcinoma?. Gastroenterology, 2023, 164, 15-18. | 1.3 | 0 |
| 1408 | Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Aheadâ€”A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117. | 4.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1409 | Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1171-1185. | 3.7 | 3 |
| 1410 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Frontiers in Medicine, 0, 9, . | 2.6 | 1 |
| 1411 | Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Journal of Immunology Research, 2022, 2022, 1-32. | 2.2 | 2 |
| 1412 | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Frontiers in Immunology, 0, 13, . | 4.8 | 0 |
| 1413 | Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2022, 22, . | 2.6 | 5 |
| 1414 | Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International, 2023, 4, 13-27. | 1.3 | 0 |
| 1415 | Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (United States), 2022, 101, e31479. | 1.0 | 2 |
| 1416 | Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. , 2022, 1, 225-234. | | 3 |
| 1418 | Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. Clinical and Experimental Medicine, 0, , . | 3.6 | 1 |
| 1419 | Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, . | 2.0 | 1 |
| 1421 | Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Advances in Therapy, 0, , . | 2.9 | 1 |
| 1422 | Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology, 2022, 18, 3769-3782. | 2.4 | 11 |
| 1423 | Evolution of systemic therapy for advanced-stage hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 899-902. | 1.5 | 1 |
| 1424 | Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. Journal of Gastrointestinal Oncology, 2022, . | 1.4 | 1 |
| 1425 | Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. Journal of Cancer, 2022, 13, 3539-3553. | 2.5 | 2 |
| 1426 | A new and rare type of hepatocellular carcinoma: Survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma. Pathology Research and Practice, 2023, 241, 154260. | 2.3 | 0 |
| 1427 | Research progress on the role of cholesterol in hepatocellular carcinoma. European Journal of Pharmacology, 2023, 938, 175410. | 3.5 | 4 |
| 1428 | Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188841. | 7.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1429 | Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188848. | 7.4 | 3 |
| 1430 | The role of circadian gene timeless in gastrointestinal cancers. Gene Reports, 2023, 30, 101722. | 0.8 | 0 |
| 1431 | 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126. | 3.4 | 44 |
| 1432 | The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137. | | 0 |
| 1433 | Interdisciplinary Approach in Hepatobiliary Cancers. , 2022, , 1-40. | | 0 |
| 1434 | Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |
| 1436 | Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers, 2022, 14, 5834. | 3.7 | 24 |
| 1437 | Reduced tumor stiffness quantified by tomoelastography as a predicative marker for glypican-3-positive hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |
| 1438 | Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opinion on Investigational Drugs, 2022, 31, 1151-1167. | 4.1 | 3 |
| 1439 | Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Frontiers in Oncology, 0, 12, . | 2.8 | 2 |
| 1440 | Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1187-1200. | 3.7 | 2 |
| 1441 | Highlighting novel targets in immunotherapy for liver cancer. Expert Review of Gastroenterology and Hepatology, 2022, 16, 1029-1041. | 3.0 | 3 |
| 1442 | ACR Appropriateness CriteriaÂ® Management of Liver Cancer: 2022 Update. Journal of the American College of Radiology, 2022, 19, S390-S408. | 1.8 | 1 |
| 1443 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2023, 41, 1434-1443. | 1.6 | 50 |
| 1444 | CD8+ T cell exhaustion and cancer immunotherapy. Cancer Letters, 2023, 559, 216043. | 7.2 | 18 |
| 1445 | The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology, 2022, 18, 4119-4136. | 2.4 | 4 |
| 1446 | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2023, 29, 754-763. | 7.0 | 10 |
| 1447 | Immune Checkpoint Inhibitor Therapy inÂOncology. JACC: CardioOncology, 2022, 4, 579-597. | 4.0 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1449 | Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Current Pharmaceutical Design, 2023, 29, 2-14. | 1.9 | 2 |
| 1450 | In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer. Scientific Reports, 2022, 12, . | 3.3 | 2 |
| 1451 | An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends, 2022, 16, 405-425. | 3.4 | 7 |
| 1452 | Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1247-1261. | 3.7 | 7 |
| 1453 | Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1263-1278. | 3.7 | 2 |
| 1454 | Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. Diagnostics, 2022, 12, 3157. | 2.6 | 6 |
| 1455 | Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. Aging, 0, , . | 3.1 | 0 |
| 1456 | Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 4.8 | 3 |
| 1457 | PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology, 0, 13, . | 4.8 | 36 |
| 1458 | Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers, 2023, 15, 50. | 3.7 | 5 |
| 1459 | HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response. European Radiology, 2023, 33, 4389-4400. | 4.5 | 2 |
| 1460 | Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 2022, 10, 3202. | 3.2 | 26 |
| 1461 | Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology, 2023, 102, 151284. | 3.6 | 8 |
| 1462 | Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 4.8 | 2 |
| 1463 | Biomarkers Use and Development in Hepatology: Insights on the Latest Applications. Cells, 2023, 12, 104. | 4.1 | 0 |
| 1464 | Anti-atherogenic and cardio-protective properties of sweet melon (Cucumis melo. L. Inodorus) seed extract on high fat diet induced obesity in male wistar rats. BMC Complementary Medicine and Therapies, 2022, 22, . | 2.7 | 2 |
| 1465 | Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480. | 3.2 | 10 |
| 1466 | Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts. Modern Pathology, 2023, 36, 100042. | 5.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1467 | Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology, 2023, 30, 1363-1380. | 2.2 | 1 |
| 1468 | Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology, 0, 13, . | 3.5 | 13 |
| 1469 | Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers, 2023, 15, 348. | 3.7 | 3 |
| 1470 | Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Frontiers in Oncology, 0, 12, . | 2.8 | 1 |
| 1471 | A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. Cell Discovery, 2023, 9, . | 6.7 | 8 |
| 1472 | Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 1417. | 4.1 | 10 |
| 1473 | Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482211482. | 3.2 | 1 |
| 1474 | Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Frontiers in Immunology, 0, 13, . | 4.8 | 9 |
| 1475 | Phase 1 dose escalation study of <scp>FGFR4</scp> inhibitor in combination with pembrolizumab in advanced solid tumors patients. Cancer Medicine, 0, , . | 2.8 | 1 |
| 1476 | Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 3 |
| 1477 | Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. Journal of Oncology, 2023, 2023, 1-13. | 1.3 | 0 |
| 1478 | Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Frontiers in Oncology, 0, 12, . | 2.8 | 6 |
| 1479 | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current Oncology, 2023, 30, 749-757. | 2.2 | 4 |
| 1480 | Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatology International, 2023, 17, 406-416. | 4.2 | 10 |
| 1481 | In situ Vaccination Followed by Intramuscular poly-ICLC Injections for the Treatment of Hepatocellular Carcinoma in Mouse Models. Pharmacological Research, 2023, , 106646. | 7.1 | 0 |
| 1482 | A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Antiâ€“PD-1 Immunotherapy against Hepatocarcinoma. Journal of Immunology, 2023, 210, 681-695. | 0.8 | 2 |
| 1483 | Soluble programmed death ligandâ€1â€induced immunosuppressive effects on chimeric antigen receptorâ€natural killer cells targeting Glypicanâ€3 in hepatocellular carcinoma. Immunology, 2023, 169, 204-218. | 4.4 | 4 |
| 1484 | HMMR potential as a diagnostic and prognostic biomarker of cancerâ€”speculation based on a pan-cancer analysis. Frontiers in Surgery, 0, 9, . | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1485 | Peripheral and tumorâ€infiltrating immune cells are correlated with patient outcomes in ovarian cancer. Cancer Medicine, 2023, 12, 10045-10061. | 2.8 | 1 |
| 1486 | Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Review of Gastroenterology and Hepatology, 2023, 17, 31-43. | 3.0 | 4 |
| 1487 | Microbiome and Metabolomics in Liver Cancer: Scientific Technology. International Journal of Molecular Sciences, 2023, 24, 537. | 4.1 | 13 |
| 1488 | Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. European Journal of Internal Medicine, 2023, 111, 37-46. | 2.2 | 3 |
| 1489 | Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. Cancers, 2023, 15, 260. | 3.7 | 1 |
| 1490 | Fibrosis and Immunotherapy in Hepatocellular Carcinoma. , 2023, , 255-281. | | 1 |
| 1491 | Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers, 2023, 15, 654. | 3.7 | 7 |
| 1492 | Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. International Journal of Molecular Sciences, 2023, 24, 2358. | 4.1 | 5 |
| 1493 | The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 4 |
| 1494 | Tumor immunology. , 2023, , 245-452. | | 0 |
| 1495 | The phospholipid flippase <scp>ATP9A</scp> enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. Journal of Pathology, 2023, 260, 17-31. | 4.5 | 3 |
| 1496 | Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 854. | 3.7 | 2 |
| 1497 | Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon. Hepatology, 2023, 77, 1074-1077. | 7.3 | 0 |
| 1498 | Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 39-58. | 0.7 | 1 |
| 1499 | Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Frontiers in Oncology, 0, 12, . | 2.8 | 1 |
| 1500 | Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. Pathology Research and Practice, 2023, 244, 154338. | 2.3 | 3 |
| 1501 | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?. International Journal of Molecular Sciences, 2023, 24, 2685. | 4.1 | 6 |
| 1502 | Immunotherapies in rare cancers. Molecular Cancer, 2023, 22, . | 19.2 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1503 | Novel insights into the impact of liver inflammatory responses on primary liver cancer development. Liver Research, 2023, 7, 26-34. | 1.4 | 1 |
| 1504 | The application of nanoparticles in immunotherapy for hepatocellular carcinoma. Journal of Controlled Release, 2023, 355, 85-108. | 9.9 | 3 |
| 1505 | A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncology, 2022, 18, 4465-4471. | 2.4 | 1 |
| 1506 | KLF4 loss in hepatocellular carcinoma: Improving prognostic prediction and correlating immune infiltrates. Frontiers in Genetics, 0, 14, . | 2.3 | 0 |
| 1507 | Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment. European Journal of Radiology, 2023, 162, 110784. | 2.6 | 1 |
| 1508 | A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma. Journal of Pharmacological Sciences, 2023, 152, 69-75. | 2.5 | 1 |
| 1509 | Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 2261-2271. | 3.3 | 1 |
| 1511 | Liver Stereotactic Body Radiotherapy (SBRT). , 2022, , 349-362. | | 0 |
| 1512 | Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-Î³/NSDHL/SREBP1/TGF-Î²1 axis in hepatocellular carcinoma. Biomedicine and Pharmacotherapy, 2023, 159, 114254. | 5.6 | 4 |
| 1515 | Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. Oncology Research, 2022, 30, 243-258. | 1.5 | 0 |
| 1516 | Hypoxia-associated circPRDM4 promotes immune escape via HIF-1Î± regulation of PD-L1 in hepatocellular carcinoma. Experimental Hematology and Oncology, 2023, 12, . | 5.0 | 12 |
| 1517 | Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduction and Targeted Therapy, 2023, 8, . | 17.1 | 44 |
| 1518 | Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatology Communications, 2023, 7, e0054-e0054. | 4.3 | 2 |
| 1519 | Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 19 |
| 1520 | Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. Clinical and Experimental Medicine, 2023, 23, 1881-1899. | 3.6 | 1 |
| 1521 | Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clinical and Experimental Medicine, 2023, 23, 1901-1916. | 3.6 | 11 |
| 1522 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 3625. | 4.1 | 1 |
| 1524 | Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2023, 12, 309-320. | 7.7 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1525 | Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, 0, Volume 10, 267-279. | 3.7 | 1 |
| 1527 | Systemic therapy in advanced hepatocellular carcinoma. Clinical and Molecular Hepatology, 2023, 29, 516-519. | 8.9 | 3 |
| 1528 | Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma. European Surgical Research, 2023, 64, 268-277. | 1.3 | 2 |
| 1529 | T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. , 2023, 11, e006493. | | 4 |
| 1530 | Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advances in Therapy, 2023, 40, 1686-1704. | 2.9 | 3 |
| 1531 | CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current Oncology, 2023, 30, 2653-2672. | 2.2 | 2 |
| 1532 | Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. Cancer Immunology, Immunotherapy, 2023, 72, 2137-2149. | 4.2 | 2 |
| 1533 | Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 0, Volume 10, 303-313. | 3.7 | 3 |
| 1534 | Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research, 2023, 43, 1377-1384. | 1.1 | 1 |
| 1536 | Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy, 2023, 15, 353-365. | 2.0 | 3 |
| 1537 | Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. , 2023, 2, 36-51. | | 1 |
| 1538 | Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene, 2023, 42, 1051-1057. | 5.9 | 4 |
| 1539 | The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2023, 22, 153303382311597. | 1.9 | 3 |
| 1540 | Immune Strategies for Gastrointestinal Cancer: HCC. , 2023, , 163-176. | | 0 |
| 1541 | An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. International Journal of Molecular Sciences, 2023, 24, 5002. | 4.1 | 6 |
| 1544 | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. Vaccines, 2023, 11, 614. | 4.4 | 4 |
| 1545 | Current Advances in Immune Checkpoint Therapy. , 0, , . | | 0 |
| 1546 | Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma. Heliyon, 2023, 9, e14460. | 3.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1547 | Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers, 2023, 15, 1680. | 3.7 | 8 |
| 1548 | Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1407-1424. | 3.3 | 0 |
| 1549 | FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Journal of Hepatology, 2023, 79, 109-125. | 3.7 | 20 |
| 1550 | The Multifaceted Roles of Macrophages in NAFLD Pathogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2023, 15, 1311-1324. | 4.5 | 13 |
| 1551 | Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers, 2023, 3, 121-160. | 1.9 | 2 |
| 1552 | Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis. BMC Cancer, 2023, 23, . | 2.6 | 3 |
| 1553 | Immunotherapy for advanced or recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 405-424. | 2.0 | 0 |
| 1554 | Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 1551-1568. | 3.3 | 5 |
| 1555 | A novel risk score model based on pyroptosis-related genes for predicting survival and immunogenic landscape in hepatocellular carcinoma. Aging, 0, , . | 3.1 | 1 |
| 1556 | A key driver to promote HCC: Cellular crosstalk in tumor microenvironment. Frontiers in Oncology, 0, 13, . | 2.8 | 4 |
| 1557 | The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC. Journal of Hepatocellular Carcinoma, 0, Volume 10, 447-457. | 3.7 | 1 |
| 1558 | Combination immunotherapy for hepatocellular carcinoma. Journal of Hepatology, 2023, 79, 506-515. | 3.7 | 46 |
| 1559 | Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. , 2023, , . | | 0 |
| 1560 | Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. International Immunopharmacology, 2023, 118, 110019. | 3.8 | 15 |
| 1561 | Exosome-derived circCCAR1 promotes CD8â€‰+â€‰T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Molecular Cancer, 2023, 22, . | 19.2 | 47 |
| 1562 | Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology, 0, 14, . | 3.5 | 3 |
| 1563 | Immunotherapies for advanced hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, . | 3.5 | 4 |
| 1564 | Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387. | | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1565 | Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist, 2023, 28, 714-721. | 3.7 | 2 |
| 1566 | High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16, 63-81. | 4.5 | 1 |
| 1567 | The predictive value of <scp>PDâ€Ł1</scp> expression in patients with advanced hepatocellular carcinoma treated with <scp>PD</scp>â€ł/<scp>PDâ€Ł1</scp> inhibitors: A systematic review and metaâ€ anâ€ alysis. Cancer Medicine, 2023, 12, 9282-9292. | 2.8 | 8 |
| 1568 | T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. Liver Cancer International, 2023, 4, 58-72. | 1.3 | 0 |
| 1569 | Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discovery, 2023, 9, . | 4.7 | 7 |
| 1570 | Management of hepatocellular carcinomaÂfrom diagnosis in routine clinical practice. Hepatic Oncology, 2022, 9, . | 4.2 | 0 |
| 1571 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines, 2023, 11, 1020. | 3.2 | 6 |
| 1572 | Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 1573 | The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer. International Journal of Molecular Sciences, 2023, 24, 6314. | 4.1 | 0 |
| 1574 | Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion. Advanced Science, 2023, 10, . | 11.2 | 18 |
| 1576 | Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC Gastroenterology, 2023, 23, . | 2.0 | 0 |
| 1577 | Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors. Digestive and Liver Disease, 2023, 55, 938-944. | 0.9 | 2 |
| 1578 | Another prognostic marker for hepatocellular carcinoma. Hepatology International, 2023, 17, 279-280. | 4.2 | 0 |
| 1579 | Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology, 2023, 307, . | 7.3 | 16 |
| 1580 | Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Therapeutics and Clinical Risk Management, 0, Volume 19, 329-339. | 2.0 | 2 |
| 1581 | Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. Molecular and Cellular Biochemistry, 2024, 479, 127-170. | 3.1 | 1 |
| 1582 | Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. Journal of Medicinal Chemistry, 2023, 66, 4275-4293. | 6.4 | 7 |
| 1583 | Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer, 2023, 12, 405-444. | 7.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1584 | Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents. Journal of Hepatocellular Carcinoma, 0, Volume 10, 587-598. | 3.7 | 1 |
| 1585 | Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatology International, 2023, 17, 753-764. | 4.2 | 11 |
| 1586 | Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World Journal of Gastrointestinal Oncology, 0, 15, 689-699. | 2.0 | 1 |
| 1588 | Normalization of Tumor Vessels by Lenvatinibâ€Based Metalloâ€Nanodrugs Alleviates Hypoxia and Enhances Calreticulinâ€Mediated Immune Responses in Orthotopic HCC and Organoids. Small, 2023, 19, . | 10.0 | 5 |
| 1589 | Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation. Engineering, 2023, 29, 59-72. | 6.7 | 8 |
| 1590 | Role of ferroptosis and its non-coding RNA regulation in hepatocellular carcinoma. Frontiers in Pharmacology, 0, 14, . | 3.5 | 1 |
| 1591 | Role of Î²-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma. Cancers, 2023, 15, 2311. | 3.7 | 6 |
| 1592 | Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473. | 2.3 | 1 |
| 1594 | Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. Oncogenesis, 2023, 12, . | 4.9 | 1 |
| 1595 | Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma. , 0, , . | | 0 |
| 1596 | Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints. Frontiers in Immunology, 0, 14, . | 4.8 | 4 |
| 1597 | Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 7640. | 4.1 | 5 |
| 1598 | Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Mediators of Inflammation, 2023, 2023, 1-23. | 3.0 | 3 |
| 1599 | Histone chaperone SSRP1 is required for apoptosis inhibition and mitochondrial function in HCC via transcriptional promotion of TRAP1. Biochemistry and Cell Biology, 0, , . | 2.0 | 0 |
| 1600 | Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma. Cancer Letters, 2023, 563, 216192. | 7.2 | 4 |
| 1601 | Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. Frontiers in Pharmacology, 0, 14, . | 3.5 | 2 |
| 1602 | Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 2571-2599. | 3.3 | 5 |
| 1603 | Structural insights into N-heterocyclic moieties as an anticancer agent against hepatocellular carcinoma: An exhaustive perspective. Mini-Reviews in Medicinal Chemistry, 2023, 23, . | 2.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1604 | Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity. Cancer Research, 2023, 83, 2283-2296. | 0.9 | 1 |
| 1605 | Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports, 2023, 5, 100747. | 4.9 | 8 |
| 1606 | Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis. Frontiers in Immunology, 0, 14, . | 4.8 | 1 |
| 1607 | Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy. Cancer Letters, 2023, 564, 216186. | 7.2 | 6 |
| 1608 | Navigating the immunometabolic heterogeneity of B cells in murine hepatocellular carcinoma at single cell resolution. International Immunopharmacology, 2023, 120, 110257. | 3.8 | 0 |
| 1609 | Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity. Expert Review of Anticancer Therapy, 2023, 23, 673-683. | 2.4 | 0 |
| 1610 | Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 6 |
| 1611 | Efficacy and safety of immune checkpoint inhibitors combined with anti-VEGF therapy in the treatment of unresectable or advanced liver cancer: a systematic review. Immunopharmacology and Immunotoxicology, 0, , 1-10. | 2.4 | 0 |
| 1612 | Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes. Clinics and Research in Hepatology and Gastroenterology, 2023, 47, 102149. | 1.5 | 2 |
| 1613 | The clinical application of immuno-therapeutics. , 2024, , 237-288.e7. | | 0 |
| 1614 | Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Frontiers in Immunology, 0, 14, . | 4.8 | 6 |
| 1615 | Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis. Cureus, 2023, , . | 0.5 | 0 |
| 1616 | Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 2 |
| 1617 | Chinese Medicine Enhancing Response Rates to Immunosuppressant PD-L1 Inhibitor and Improving the Quality of Life of Hepatocellular Carcinoma-Bearing Mice. Iranian Journal of Pharmaceutical Research, 2023, 22, . | 0.5 | 0 |
| 1618 | Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study. Radiation Oncology, 2023, 18, . | 2.7 | 0 |
| 1619 | Identification of Cytochrome P450 2E1 as a Novel Target in Glioma and Development of Its Inhibitor as an Antiâ€Tumor Agent. Advanced Science, 2023, 10, . | 11.2 | 3 |
| 1620 | Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma. JHEP Reports, 2023, 5, 100811. | 4.9 | 9 |
| 1621 | CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1622 | Global research trends on immunotherapy in cancer: A bibliometric analysis. Human Vaccines and Immunotherapeutics, 2023, 19, . | 3.3 | 2 |
| 1623 | Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy. BMC Cancer, 2023, 23, . | 2.6 | 1 |
| 1624 | The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma. Medicina (Lithuania), 2023, 59, 1150. | 2.0 | 2 |
| 1625 | Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. BMC Cancer, 2023, 23, . | 2.6 | 3 |
| 1626 | Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology, 2023, 30, 5863-5875. | 2.2 | 4 |
| 1627 | Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study. Discover Oncology, 2023, 14, . | 2.1 | 0 |
| 1628 | Brazilian Landscape of Hepatocellular Carcinoma. JCO Global Oncology, 2023, , . | 1.8 | 0 |
| 1629 | Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Research Communications, 2023, 3, 1312-1317. | 1.7 | 4 |
| 1630 | Recent advances of three-dimensional bioprinting technology in hepato-pancreato-biliary cancer models. Frontiers in Oncology, 0, 13, . | 2.8 | 5 |
| 1631 | Dihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy. Frontiers of Medicine, 2023, 17, 729-746. | 3.4 | 2 |
| 1632 | Potential biomarkers for immunotherapy in non-small-cell lung cancer. Cancer and Metastasis Reviews, 0, , . | 5.9 | 1 |
| 1633 | Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 7.1 | 8 |
| 1634 | Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies. Cancers, 2023, 15, 2624. | 3.7 | 1 |
| 1635 | Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib. Technology in Cancer Research and Treatment, 2023, 22, 153303382311667. | 1.9 | 0 |
| 1636 | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy. Frontiers in Immunology, 0, 14, . | 4.8 | 5 |
| 1637 | Refining the approach to down-staging for hepatocellular carcinoma prior to liver transplantation: Patient selection, local-regional treatments, and systemic therapies. Hepatology, 0, Publish Ahead of Print, . | 7.3 | 0 |
| 1638 | A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 2023, 29, 2816-2825. | 7.0 | 2 |
| 1639 | HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1640 | Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 0, 11, . | 3.7 | 2 |
| 1641 | Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model. Journal of Cancer Research and Clinical Oncology, 2023, 149, 10685-10700. | 2.5 | 1 |
| 1642 | New techniques: a roadmap for the development of HCC immunotherapy. Frontiers in Immunology, 0, 14, . | 4.8 | 1 |
| 1643 | Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Caseâ€“Control Study. Targeted Oncology, 2023, 18, 601-610. | 3.6 | 0 |
| 1644 | New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma. Drugs, 2023, 83, 1091-1109. | 10.9 | 2 |
| 1645 | Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma. European Journal of Medical Research, 2023, 28, . | 2.2 | 0 |
| 1647 | The Current Landscape of Therapies for Hepatocellular Carcinoma. Carcinogenesis, 0, , . | 2.8 | 1 |
| 1648 | Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer. International Journal of Molecular Sciences, 2023, 24, 11387. | 4.1 | 4 |
| 1649 | Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 5 |
| 1650 | Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution. Life, 2023, 13, 1562. | 2.4 | 0 |
| 1651 | Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts. Frontiers in Immunology, 0, 14, . | 4.8 | 2 |
| 1652 | Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect. Critical Reviews in Oncology/Hematology, 2023, 189, 104070. | 4.4 | 2 |
| 1653 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations. Therapeutic Advances in Medical Oncology, 2023, 15, . | 3.2 | 2 |
| 1654 | Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1105-1127. | 3.7 | 0 |
| 1655 | Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma. Liver Cancer, 2023, 12, 189-197. | 7.7 | 3 |
| 1657 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet, The, 2023, 402, 1133-1146. | 13.7 | 68 |
| 1658 | Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 11799. | 4.1 | 2 |
| 1659 | <scp>SMAD4</scp> regulates the progression of cholangiocarcinoma by modulating the expression of <scp>STING1</scp>. Journal of Cellular and Molecular Medicine, 0, , . | 3.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1660 | Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1209-1222. | 3.7 | 1 |
| 1661 | A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 1662 | Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab. Frontiers in Immunology, 0, 14, . | 4.8 | 1 |
| 1663 | Immunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience. Journal of Gastrointestinal Surgery, 2023, 27, 2126-2134. | 1.7 | 1 |
| 1664 | Bibliometric study of immunotherapy for hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 1665 | Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma. JAMA Oncology, 2024, 10, 395. | 7.1 | 9 |
| 1666 | The effect of liver disease on hepatic microenvironment and implications for immune therapy. Frontiers in Pharmacology, 0, 14, . | 3.5 | 2 |
| 1667 | Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors. Medicina (Lithuania), 2023, 59, 1427. | 2.0 | 1 |
| 1668 | Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 14113-14123. | 2.5 | 1 |
| 1669 | Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer, 2024, 13, 169-180. | 7.7 | 5 |
| 1670 | The role of gut microbiome and fecal microbiota transplantation in liver cancer and related complications: mechanisms and therapeutic potentials. Hepatoma Research, 0, , . | 1.5 | 0 |
| 1671 | Evolution of Systemic Therapy in Advanced Hepatocellular Carcinoma. Surgical Oncology Clinics of North America, 2024, 33, 73-85. | 1.5 | 1 |
| 1672 | Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study. Scientific Reports, 2023, 13, . | 3.3 | 0 |
| 1673 | Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. , 2023, 11, e007106. | | 0 |
| 1674 | Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Medicine, 2023, 21, . | 5.5 | 1 |
| 1675 | Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology. International Journal of Molecular Sciences, 2023, 24, 13274. | 4.1 | 3 |
| 1676 | Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2023, 23, . | 2.6 | 4 |
| 1677 | CD5 Expression Dynamically Changes During the Differentiation of Human CD8<sup>+</sup> T Cells Predicting Clinical Response to Immunotherapy. Immune Network, 2023, 23, . | 3.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1678 | Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma. , 2023, 2, 163-169. | | 0 |
| 1679 | Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. Cancers, 2023, 15, 4345. | 3.7 | 2 |
| 1680 | The Era of Immunotherapy in Hepatocellular Carcinoma: The New Mission and Challenges of Magnetic Resonance Imaging. Cancers, 2023, 15, 4677. | 3.7 | 0 |
| 1681 | Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current Oncology, 2023, 30, 8665-8685. | 2.2 | 0 |
| 1682 | Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease. Life, 2023, 13, 1987. | 2.4 | 2 |
| 1683 | Advances in radiotherapy and immunity in hepatocellular carcinoma. Journal of Translational Medicine, 2023, 21, . | 4.4 | 5 |
| 1684 | Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 780-798. | 27.6 | 5 |
| 1685 | Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?. Therapeutic Advances in Medical Oncology, 2023, 15, . | 3.2 | 0 |
| 1686 | Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2023, 12, . | 3.7 | 2 |
| 1687 | Single-cell and genetic multi-omics analysis combined with experiments confirmed the signature and potential targets of cuproptosis in hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 0, 11, . | 3.7 | 0 |
| 1688 | Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?. Digestive and Liver Disease, 2023, , . | 0.9 | 1 |
| 1689 | Lactate score classification of hepatocellular carcinoma helps identify patients with tumors that respond to immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2024, 47, 175-188. | 4.4 | 0 |
| 1690 | Real-World Use of Immunotherapy for Hepatocellular Carcinoma. Journal of Pragmatic and Observational Research, 0, Volume 14, 63-74. | 1.5 | 1 |
| 1691 | Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers, 2023, 15, 4574. | 3.7 | 4 |
| 1692 | Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology, 2023, 20, 864-884. | 27.6 | 14 |
| 1693 | Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 2 |
| 1694 | Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1. MAbs, 2023, 15, . | 5.2 | 0 |
| 1695 | Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study. Cancer Immunology, Immunotherapy, 2023, 72, 3609-3619. | 4.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1696 | <scp>ERS</scp>: A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma. Liver International, 2023, 43, 2538-2547. | 3.9 | 3 |
| 1697 | Identification and verification of novel immune-related ferroptosis signature with excellent prognostic predictive and clinical guidance value in hepatocellular carcinoma. Frontiers in Genetics, 0, 14, . | 2.3 | 0 |
| 1698 | Drug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma. , 2023, 3, 189-199. | | 0 |
| 1699 | Amino Acids Transport as an Index of Cancer Stem Cells Dysregulation. , 2023, , 1-24. | | 0 |
| 1700 | Hepatitis Viruses: Hepatocellular Carcinoma. , 2023, , 1-36. | | 0 |
| 1701 | PIAS3 promotes ferroptosis by regulating TXNIP via TGF-Î² signaling pathway in hepatocellular carcinoma. Pharmacological Research, 2023, 196, 106915. | 7.1 | 0 |
| 1702 | The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology, 0, , . | 7.3 | 1 |
| 1703 | Management of Hepatocellular Carcinoma: The East-West Difference. Current Chinese Science, 2023, 03, . | 0.5 | 0 |
| 1704 | Downstaging Hepatocellular Carcinoma before Transplantation. Surgical Oncology Clinics of North America, 2023, , . | 1.5 | 0 |
| 1705 | The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival. Journal of Cancer Research and Therapeutics, 2023, 19, 1103-1108. | 0.9 | 0 |
| 1707 | Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1689-1708. | 3.7 | 1 |
| 1708 | Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers, 2023, 15, 4867. | 3.7 | 0 |
| 1709 | The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers, 2023, 15, 4875. | 3.7 | 0 |
| 1710 | Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/Î²-Catenin Mutations. Liver Cancer, 0, , 1-21. | 7.7 | 0 |
| 1711 | Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1827-1837. | 3.7 | 1 |
| 1712 | Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 1713 | Unveiling the Role of Tumor-Infiltrating T Cells and Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review. Cancers, 2023, 15, 5046. | 3.7 | 1 |
| 1714 | Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation. BMC Cancer, 2023, 23, . | 2.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1715 | Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study. International Immunopharmacology, 2023, 125, 111019. | 3.8 | 0 |
| 1716 | Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Therapeutic Advances in Medical Oncology, 2023, 15, . | 3.2 | 0 |
| 1717 | Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study. Therapeutics and Clinical Risk Management, 0, Volume 19, 853-863. | 2.0 | 1 |
| 1718 | Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 2023, 15, 5131. | 3.7 | 0 |
| 1719 | Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46. | 27.6 | 1 |
| 1720 | A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma. Scientific Reports, 2023, 13, . | 3.3 | 0 |
| 1721 | Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report. Journal of Surgical Case Reports, 2023, 2023, . | 0.4 | 0 |
| 1722 | Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2023, 42, . | 8.6 | 0 |
| 1723 | Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study. Frontiers in Oncology, 0, 13, . | 2.8 | 0 |
| 1724 | Single-cell and spatial architecture of primary liver cancer. Communications Biology, 2023, 6, . | 4.4 | 0 |
| 1725 | Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1911-1922. | 3.7 | 0 |
| 1726 | Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. Translational Oncology, 2024, 40, 101851. | 3.7 | 1 |
| 1727 | Tâ€cell receptor sequencing reveals hepatocellular carcinoma immune characteristics according to Barcelona Clinic liver cancer stages within liver tissue and peripheral blood. Cancer Science, 2024, 115, 94-108. | 3.9 | 0 |
| 1728 | Advances in Immunotherapy for Hepatocellular Carcinoma (HCC). Current Oncology, 2023, 30, 9789-9812. | 2.2 | 1 |
| 1729 | Role of Immunological Cells in Hepatocellular Carcinoma Disease and Associated Pathways. ACS Pharmacology and Translational Science, 2023, 6, 1801-1816. | 4.9 | 1 |
| 1730 | The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments. Journal of Clinical Medicine, 2023, 12, 7469. | 2.4 | 0 |
| 1731 | Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study. International Immunopharmacology, 2024, 127, 111337. | 3.8 | 0 |
| 1733 | Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 10, 1955-1971. | 3.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1734 | Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review). Experimental and Therapeutic Medicine, 2023, 26, . | 1.8 | 0 |
| 1735 | Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment. Phytomedicine, 2024, 123, 155189. | 5.3 | 1 |
| 1736 | Effect of probiotics and fecal microbiota transplantation in dirty rats with established primary liver cancer. Future Microbiology, 2024, 19, 117-129. | 2.0 | 0 |
| 1737 | Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Tzu Chi Medical Journal, 0, , . | 1.1 | 0 |
| 1738 | Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization â€“ Implications in treatment outcomes. European Journal of Cancer, 2024, 196, 113442. | 2.8 | 0 |
| 1740 | Hepatocellular carcinoma recurrence: Predictors and managementâ˜†. Liver Research, 2023, , . | 1.4 | 0 |
| 1741 | Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 16773. | 4.1 | 1 |
| 1742 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2023, 24, 1399-1410. | 10.7 | 19 |
| 1743 | Biomarkers of Immunotherapy for Hepatocellular Carcinoma. Advances in Clinical Medicine, 2023, 13, 18703-18708. | 0.0 | 0 |
| 1744 | Analysis of immuneâ€related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors. International Journal of Cancer, 2024, 154, 1261-1271. | 5.1 | 0 |
| 1745 | Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine, 2024, 67, 102367. | 7.1 | 1 |
| 1746 | Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies. Surgical Oncology, 2024, 52, 102031. | 1.6 | 0 |
| 1747 | Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. Hepatology Communications, 2023, 7, . | 4.3 | 1 |
| 1748 | FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomedicine and Pharmacotherapy, 2024, 170, 115955. | 5.6 | 0 |
| 1749 | Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month. European Journal of Radiology, 2024, 170, 111266. | 2.6 | 0 |
| 1750 | Immune Checkpoint Inhibitor-Induced Liver Injury. Seminars in Liver Disease, 2023, 43, 402-417. | 3.6 | 0 |
| 1751 | Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma. Cancers, 2023, 15, 5878. | 3.7 | 1 |
| 1752 | Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, . | 4.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1753 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Annals of Oncology, 2023, , . | 1.2 | 0 |
| 1754 | Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. Oncologie, 2024, 26, 9-25. | 0.7 | 0 |
| 1755 | Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review. Cancer Cell International, 2024, 24, . | 4.1 | 0 |
| 1757 | Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape. Biomedicine and Pharmacotherapy, 2024, 171, 116203. | 5.6 | 0 |
| 1759 | Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy. Current Opinion in Organ Transplantation, 2024, 29, 144-154. | 1.6 | 1 |
| 1760 | Updates on Systemic Therapy for Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2024, 44, . | 3.8 | 0 |
| 1761 | Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Autophagy, 0, , 1-21. | 9.1 | 1 |
| 1762 | Unleashing the potential of gene signatures as prognostic and predictive tools: A step closer to personalizedÂmedicine in hepatocellular carcinoma (HCC). Cell Biochemistry and Function, 2024, 42, . | 2.9 | 0 |
| 1763 | Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio. International Immunopharmacology, 2024, 128, 111477. | 3.8 | 0 |
| 1764 | MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges. Cancers, 2024, 16, 259. | 3.7 | 0 |
| 1765 | A novel cholesterol metabolism-related ferroptosis pathway in hepatocellular carcinoma. Discover Oncology, 2024, 15, . | 2.1 | 0 |
| 1766 | Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 1767 | C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients. World Journal of Gastrointestinal Oncology, 0, 16, 61-78. | 2.0 | 0 |
| 1768 | Efficiency and safety of hepatic arterial infusion chemotherapy (<scp>HAIC</scp>) combined with antiâ€<scp>PD1</scp> therapy versus <scp>HAIC</scp> monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis. Cancer Medicine, 2024, 13, . | 2.8 | 0 |
| 1769 | A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394. Liver Cancer, 0, , 1-12. | 7.7 | 0 |
| 1770 | Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma. Immunology, 2024, 172, 21-45. | 4.4 | 0 |
| 1771 | Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition). Liver Cancer, 0, , 1-21. | 7.7 | 0 |
| 1773 | Combination of atezolizumab and bevacizumab in patients with inoperable hepatocellular cancer in real clinical practice. Meditsinskiy Sovet, 2024, , 41-48. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1774 | Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells. Scientific Reports, 2024, 14, . | 3.3 | 0 |
| 1776 | Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer. Hepatology Communications, 2024, 8, . | 4.3 | 0 |
| 1778 | Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors. Journal of Hepatocellular Carcinoma, 0, Volume 11, 207-217. | 3.7 | 0 |
| 1779 | New Opportunities in the Systemic Treatment of Hepatocellular Carcinomaâ€"Today and Tomorrow. International Journal of Molecular Sciences, 2024, 25, 1456. | 4.1 | 0 |
| 1780 | Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitiors for unresectable hepatocellular carcinoma and meta-analysis. World Journal of Gastroenterology, 0, 30, 318-331. | 3.3 | 0 |
| 1781 | A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma. JHEP Reports, 2024, 6, 101021. | 4.9 | 0 |
| 1782 | Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy. Journal of Biomedical Science, 2024, 31, . | 7.0 | 0 |
| 1783 | Case report and literature analysis: solitary HCC- recurrence in the right maxillary sinus after curative resection. Frontiers in Oncology, 0, 14, . | 2.8 | 0 |
| 1784 | Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma. Journal of Translational Medicine, 2024, 22, . | 4.4 | 0 |
| 1785 | Omics-based molecular classifications empowering in precision oncology. Cellular Oncology (Dordrecht), 0, , . | 4.4 | 0 |
| 1786 | Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma. Frontiers in Pharmacology, 0, 15, . | 3.5 | 0 |
| 1787 | Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy. World Journal of Gastrointestinal Oncology, 0, 16, 273-286. | 2.0 | 0 |
| 1788 | Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56Îµ in pan-cancer and its role and mechanism in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 16, 475-492. | 2.0 | 0 |
| 1789 | Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm, 2024, 5, . | 7.2 | 0 |
| 1790 | Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review. Journal of Cancer Research and Clinical Oncology, 2024, 150, . | 2.5 | 0 |
| 1791 | Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape. Cancers, 2024, 16, 666. | 3.7 | 0 |
| 1792 | Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy. Journal of Hepatology, 2024, 80, 792-804. | 3.7 | 0 |
| 1793 | Precision treatment in advanced hepatocellular carcinoma. Cancer Cell, 2024, 42, 180-197. | 16.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1794 | Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomarker Research, 2024, 12, . | 6.8 | 1 |
| 1796 | Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer. Investigational New Drugs, 2024, 42, 161-170. | 2.6 | 0 |
| 1797 | Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?. Journal of Hepatocellular Carcinoma, 0, Volume 11, 363-372. | 3.7 | 0 |
| 1798 | Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review. Frontiers in Immunology, 0, 15, . | 4.8 | 0 |
| 1799 | Critical Roles of the Sphingolipid Metabolic Pathway in Liver Regeneration, Hepatocellular Carcinoma Progression and Therapy. Cancers, 2024, 16, 850. | 3.7 | 0 |
| 1800 | The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocrine Reviews, 0, , . | 20.1 | 0 |
| 1801 | Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. Cell Reports Medicine, 2024, 5, 101415. | 6.5 | 0 |
| 1802 | Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Scientific Reports, 2024, 14, . | 3.3 | 0 |
| 1803 | SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics. Biomolecules, 2024, 14, 265. | 4.0 | 0 |
| 1804 | Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma. Advances in Oncology, 2024, 4, 233-246. | 0.2 | 0 |
| 1805 | Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma. BMC Gastroenterology, 2024, 24, . | 2.0 | 0 |
| 1806 | Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study. Frontiers in Oncology, 0, 14, . | 2.8 | 0 |
| 1807 | Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment. Methods in Cell Biology, 2024, , 79-97. | 1.1 | 0 |
| 1809 | S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. Journal of Experimental and Clinical Cancer Research, 2024, 43, . | 8.6 | 0 |
| 1810 | Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Liver Cancer, 0, , 1-19. | 7.7 | 0 |
| 1811 | PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma. European Journal of Medical Research, 2024, 29, . | 2.2 | 0 |
| 1812 | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of Clinical Oncology, 0, , . | 1.6 | 0 |
| 1813 | Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Letters, 2024, 588, 216799. | 7.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1814 | The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial. Nature Communications, 2024, 15, . | 12.8 | 0 |
| 1815 | Two cases of severe oral mucositis caused by atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 0, , . | 0.8 | 0 |